Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Lower levels of vitamin D in cases than controls

Source: Micronutrient subgroups. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Maternal micronutrient deficiency and congenital heart disease risk: A systematic review of observational studies

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Maternal micronutrient deficiency and congenital heart disease risk: A systematic review of observational studies

Systematic review · Birth Defects Research · 2022

Original publication title

Maternal micronutrient deficiency and congenital heart disease risk: A systematic review of observational studies

Stuart Mires; Massimo Caputo; Timothy Overton; Clare Skerritt

© 2022 The Authors. Birth Defects Research published by Wiley Periodicals LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In conclusion, there is not enough evidence to confidently determine if maternal micronutrient deficiency increases the risk of CHD in fetuses. Further studies are required with prospective or nested case control design utilizing established micronutrient reference ranges ideally collecting samples in pregnancy and postnatally. The UK‐based Surgical‐PEARL (Surgical Paediatric congEnital Anomalies Registry with Long term follow‐up) multicenter cohort study has commenced recruitment in 2022 (https://www.isrctn.com/ISRCTN12557586). This will recruit fetuses with congenital anomalies potentially requiring surgery and their biological mothers and fathers at the time of diagnosis, collecting routine clinical and imaging data, postnatal surgical data and a range of fetal, childhood and parental biosamples.

Through resources such as this and others, we aim to establish a greater evidence base to robustly answer this question.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Congenital anomalies occur in approximately 1:50 pregnancies. Around 30% are congenital heart disease (CHD), representing the most prevalent congenital anomaly (Public Health England, 2019). CHD is generally defined as a “gross structural abnormality of the heart or intrathoracic great vessels present at birth that is actually or potentially of functional significance (Mitchell et al., 1971).” The most common CHD are ventricular septal defects, atrial septal defects, transposition of the great vessels, patent ductus arteriosus (PDA) and tetralogy of Fallot (Suluba et al., 2020).

As PDA is physiological at birth, the EUROCAT congenital anomaly registry classifies PDA as CHD if persistent 6 months following birth or requiring interventional closure (EUROCAT, 2013). The potential causal molecular, genetic and environmental risk factors remain poorly understood. Approximately 20% of cases can be attributed to genetic, chromosomal or teratogenic causes. The remaining 80% are likely multifactorial including genetic and environmental factors (Blue et al., 2012). Congenital anomalies remain a leading cause of neonatal, infant and childhood death (Petrini et al., 2002).

Patients with CHD often require multiple and complex surgeries with long term medical therapies and follow up. These can involve significant morbidity, long term mortality and substantial cost (Tennant et al., 2010). Primary prevention of CHD would significantly reduce these patient and clinical burdens (Botto & Correa, 2003). However, this requires a greater understanding of causative factors in CHD.

From Day 18 of human embryonic development, the endocardial progenitor cells form heart tubes which ultimately fuse, fold, loop and septate to form the embryonic heart. The heart beats from Day 22, with the critical sensitive period for cardiovascular development generally recognized as between Weeks 3 and 8 of embryonic development (Moore et al., 2020). These processes are under the control of a number of transcription factors, genes and signaling pathways all influenced by genetic and environmental factors (Suluba et al., 2020).

Micronutrients are essential trace elements and vitamins (Shenkin, 2006). Vitamin and micronutrient supplementation in pregnancy is recommended by the Royal College of Obstetricians and Gynecologists (RCOG) and National Institute for Health and Care Excellence (NICE) in the United Kingdom. These include folate before pregnancy and throughout the first 12 weeks predominantly to reduce the risk of neural tube defects and vitamin D to improve growth and reduce deficiency in neonates (NICE, 2014, 2017; RCOG, 2014). Micronutrients play essential roles in intracellular and cellular signaling and growth, and as such facilitate development.

Deficiencies may arise secondary to dietary and physiological factors. Animal studies assessing deficiencies have shown increased rates of congenital anomalies (McArdle & Ashworth, 1999). Studies of CHD in animal models show maternal micronutrient deficiencies including iron and vitamin A lead to increased rates in offspring (Joshi et al., 2020; Kalisch‐Smith et al., 2021). Assessment in these models suggests alterations in signaling pathways including retinoic acid signaling or epigenetic modifications potentially drive pathogenesis. This can be prevented through micronutrient administration (Joshi et al., 2020; Kalisch‐Smith et al., 2021).

Systematic review and meta‐analyses of folate and multivitamin supplementation in pregnancy and the periconceptual period have illustrated reductions in CHD and cardiovascular anomalies, neural tube defects, limb defects, orofacial clefts and urinary tract anomalies in human fetuses (Botto et al., 2004; Feng et al., 2015; Ingrid Goh et al., 2006). However, the included observational studies largely assess supplementation and do not ascertain maternal micronutrient levels.

To our knowledge, a systematic review of maternal micronutrient deficiencies in CHD has not been undertaken previously. We therefore aim to critically appraise available literature to address the question of whether maternal micronutrient deficiencies increase the risk of fetal CHD.

Source: INTRODUCTION Source: INTRODUCTION Source: INTRODUCTION Source: INTRODUCTION

Study methods

What methods does the paper describe?

2.1

Eligibility criteria

2.1.1
Study design

The overarching question addressed in this systematic review was do maternal micronutrient deficiencies increase the risk of fetal CHD? Observational studies were included. It was not anticipated that data from randomized control trials or controlled trials would be available. Case series and case reports were excluded due to high risk of bias.

2.1.2
Population

The target population was pregnant biological mothers of fetuses. Studies including surrogate mothers or pregnancies with egg donation were excluded due to the potential influence of micronutrient levels in the donor or surrogate. The exposure was maternal micronutrient level measured through serum or hair analysis in pregnancy or the postpartum period. Micronutrients in included studies were vitamin A, vitamin B 12, vitamin D, folate, iron, selenium, copper, and zinc.

2.1.3
Outcomes

The outcome assessed was a fetus, neonate or child with CHD. CHD was diagnosed antenatally though fetal echocardiography or postnatally through echocardiography, clinical assessment, cardiac catheterization or surgery.

2.2

Information sources and search strategy

This systematic review protocol was registered at PROSPERO (registration number CRD42021276699). We used the Preferred Reporting Items for Systematic review and Meta‐Analysis (PRISMA) 2020 checklist to develop this systematic review (PRISMA, 2020). A systematic literature search of electronic databases MEDLINE (via OVID), EMBASE (via OVID) and the Cochrane library was conducted to identify relevant studies published between the beginning of each database and September 7, 2021 without language restrictions. We also manually screened reference lists of included studies to identify any additional relevant literature.

A detailed search strategy for each database is outlined in Figure S1. The search strategy was developed around the MeSH descriptors: exp[heart defects, congenital], [micronutrients], [vitamins], [deficiency diseases], exp[avitaminosis]; and the key terms: [congenital heart disease*.tw.], [congenital cardiac disease*.tw.], [congenital heart anomal*.tw.], [congenital cardiac anomal*.tw.], [maternal vitamin*.tw.], [maternal micronutrient*.tw.], [maternal zinc.tw.], [maternal copper.tw.], [maternal iron.tw.] and [maternal fol*.tw.].

2.3

Study selection, data extraction and risk of bias assessment

Two authors (SM and CS) independently screened the titles and abstracts to exclude publications that did not meet the inclusion criteria. Any discrepancies were discussed. After selecting studies for inclusion, data extraction was performed by SM and checked by CS into a prior agreed form. Data extracted included author, year of publication, country of origin, study design, inclusion and exclusion criteria, case and control matching data, micronutrients analyzed, source and timing and CHD diagnosis and analysis. Information on confounding variables and adjusted data was collected.

Risk of bias assessment was assessed by SM and CS utilizing the Scottish Intercollegiate Guidelines Network (SIGN) case control study checklist and associated guidance notes (SIGN, 2012). This facilitates assessment of subject selection, exposure assessment, confounding and statistical analysis. Studies are assessed overall as high quality (++), acceptable (+) or unacceptable. Unacceptable studies were excluded from analysis due to high risk of bias.

2.4

Data synthesis

Results from studies were summarized with a narrative synthesis including summary tables due to the diversity of the included studies. Quantitative synthesis of data was not performed due to the heterogeneity of studies. Analysis was stratified by micronutrient subgroups and micronutrient levels and crude and adjusted odds ratios (OR) were presented. Where possible, if not presented in the primary study, crude ORs were calculated by the study authors. Micronutrients levels were converted into the same unit for each study to allow for direct comparison.

Published micronutrient reference ranges in pregnancy were used to define deficiency to further aid study comparisons (Cunningham, 2010).

Source: METHODS Source: METHODS Source: METHODS Source: METHODS

RESULTS: Literature search

A PRISMA flow chart of included studies is seen in Figure 1. Seven hundred and twenty‐six unique citations were identified after an initial database and reference search. Of these, 691 were excluded after title and abstract screening. The full text of 34 articles were reviewed, with 1 report not retrieved due to journal inaccessibility. A further 26 articles were excluded with reasons outlined in Figure 1, and 8 articles included in the systematic review (Dilli et al., 2018; Hobbs et al., 2005; Hu et al., 2014; Koster et al., 2018; Mokhtar et al., 2019; Ou et al., 2017; Verkleij‐Hagoort et al., 2006; Yang et al., 2020).

FIGURE 1

PRISMA 2020 flow diagram of study identification, screening, inclusion, and exclusion from Page et al. (2021)

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Literature search Source: Literature search

RESULTS: General characteristics of studies

The characteristics of the studies included in the review are summarized in Table S1. The review included data from 2,427 pregnancies, of which 1,199 had fetuses affected by CHD. Data was available on maternal levels of 8 micronutrients across studies: vitamin D, vitamin B12, folate, vitamin A, zinc, copper, selenium and ferritin. Studies originated from 5 countries: Turkey, Netherlands (2), United States, China (3), and Egypt. Studies were published in English between 2005 and 2020.

In all but 1 study, maternal micronutrient testing was through venous blood analysis of serum or plasma. One study including copper and zinc micronutrients performed testing of maternal hair. Of the six studies reporting timing of sampling, four assessed micronutrient levels postnatally. Two studies assessed levels during pregnancy between 17 weeks and delivery. In three studies CHD diagnosis was performed antenatally, four studies performed postnatal diagnosis and one study included both with cases identified through a state registry. Each study had varying proportions of diverse CHD.

The range of included studies with heterogenous micronutrient assessment, sampling technique, sample timing and CHD diagnosis and subtypes precluded quantitative synthesis of data.

Source: General characteristics of studies Source: General characteristics of studies Source: General characteristics of studies

RESULTS: Micronutrient subgroups

Table 1 summarizes differences in micronutrient levels between cases and control groups for the seven micronutrients included and ORs where calculated. Table 2 summarizes published reference ranges for micronutrients for nonpregnant and second trimester pregnant women (Cunningham, 2010).

TABLE 1

Assessment of micronutrient levels and odds ratios in included studies (NR ‐ not recorded) (Dilli et al., 2018; Hobbs et al., 2005; Hu et al., 2014; Koster et al., 2018; Mokhtar et al., 2019; Ou et al., 2017; Verkleij‐Hagoort et al., 2006; Yang et al., 2020)

MicronutrientRaw dataOdds ratiosEffect direction
Vitamin D

Dilli et al.

Mean ± SD

nmol/L

Cases: 26.7 ± 18.0

Controls: 34.4 ± 16.7

p = .02

Unable to calculate with available data

Lower levels of vitamin D in cases than controls

No definition of reference ranges for deficiency and therefore OR not calculated

Koster et al.

Median (IQR)

nmol/L

Cases: 57.8 (41.6 to 78.7)

Controls: 65.8 (40.5 to 86.6)

p = .02

Vitamin D deficient < 50 nmol/L, moderate 50 to 75 nmol/L. Utilizing adequate vitamin D group (>75 nmol/L) as reference

Crude OR for CHD in offspring:

Deficient 1.63 (1.15 to 2.32) p = .006

Moderate 1.60 (1.12 to 2.28) p = .006

aOR (age, BMI, ethnicity, smoking) for CHD in offspring:

Deficient 1.82 (1.25 to 2.66) p = .002

Moderate 1.58 (1.11 to 2.26) p = .002

Lower levels of vitamin D in cases than controls

Crude and adjusted OR suggest increased odds of CHD in offspring with vitamin D deficiency and moderate levels

Mokhtar et al.

Median (IQR)

nmol/L

Cases: 26 (10: NR)

Controls: 37 (16 to 76)

p = .002

Vitamin D deficient < 50 nmol/L, moderate 50 to 75 nmol/L. Utilizing adequate vitamin D group (>75 nmol/L) as reference a

Crude OR for CHD in offspring:

Deficient 2.48 (0.58 to 10.70) p = .22

Moderate 1.09 (0.20 to 6.01) p = .92

Lower levels of vitamin D in cases than controls

Crude OR does not provide evidence for increased odds of CHD in offspring with vitamin D deficiency or moddilli erate levels

Ferritin

Yang et al.

Median (IQR)

μg/L

Cases: 14.3 (9.7 to 30.3)

Controls 21.6 (14.1 to 39.9)

p = .003

Mixed linear regression model with control group as reference. No definitions of deficiency

Unadjusted expB:

Ferritin 0.71 (0.56 to 0.89) p = .003

Adjusted expB (maternal age, gestational age, residence, education, occupation, parity, passive smoking, folate supplement):

Ferritin 0.69 (0.54 to 0.88) p = .001

Lower levels of ferritin in cases than controls

Unadjusted and adjusted expB suggest lower levels of serum ferritin in case group prior to delivery than control group

Copper

Hu et al.

Median (IQR)

μg/g

Cases: 12.79 (8.96 to 17.25)

Controls: 8.77 (7.56 to 10.91)

p < .001

Utilized control group 5th and 95th centiles as reference ranges. Used 5th: 95th group as reference

Crude OR for CHD in offspring:

Copper <5th 0.36 (0.1 to 1.36)

Copper >95th 5.38 (2.64 to 10.95)

aOR (age, maternal residence, folic acid supplement, previous pregnancy) for CHD in offspring:

Copper <5th 0.63 (0.15 to 2.73)

Copper >95th 5.7 (2.58 to 12.61)

Higher levels of copper in cases than controls

Crude OR and aOR does not provide evidence for increased odds of CHD in offspring with low copper. Suggest high copper levels in case group compared to controls

Ou et al.

Median (IQR)

μg/L

Cases: 838.38 (778.90 to 936.98)

Controls: 896.56 (817.62 to 979.44)

p = .02

Utilized control group tertiles as reference ranges. Used low tertile as reference. Multivariable multielement logistic regression

aOR (age, parity, education, newborn gender, migration, folic acid/multivitamin, smoking, pre‐pregnancy BMI, gestation sample) for CHD in offspring:

Copper middle tertile 0.57 (0.22 to 1.47)

Copper high Tertile 0.77 (0.31 to 1.89)

Utilized control group tertiles as reference ranges. Used middle tertile as reference. a

Crude OR for CHD in offspring:

Copper low Tertile 1.91 (0.996 to 3.661) p = .0514

Lower levels of copper in cases than controls

aOR does not provide evidence for increased odds of CHD in offspring with high copper

Crude OR does not provide evidence for increased odds of CHD in offspring with low copper

Selenium

Ou et al.

Median (IQR)

μg/L

Cases: 172.90 (153.87 to 192.23)

Controls: 186.47 (172.45 to 207.34)

p < .001

Utilized control group tertiles as reference ranges. Used low tertile as reference. Multivariable multielement logistic regression

aOR (age, parity, education, newborn gender, migration, folic acid/multivitamin, smoking, pre‐pregnancy BMI, gestation sample) for CHD in offspring:

Selenium middle tertile 0.55 (0.22 to 1.38)

Selenium high tertile 0.25 (0.08 to 0.77)

Utilized control group tertiles as reference ranges. Used middle tertile as reference a

Crude OR for CHD in offspring:

Selenium low tertile 2.17 (1.15 to 4.11) p = .0171

Lower levels of selenium in cases than controls

aOR suggest decreased odds of CHD in offspring with higher selenium

Crude OR suggest increased odds of CHD in offspring with lower selenium

Zinc

Dilli et al.

Mean ± SD

μg/DL

Cases: 86.0 ± 15.3

Controls: 69.4 ± 15.1

p < .001

Unable to calculate with available data

Higher levels of zinc in cases than controls

No definition of reference ranges for deficiency and therefore OR not calculated

Hu et al.

Median (IQR)

μg/g

Cases: 180.01 (144.59 to 264.39)

Controls: 166.44 (142.02 to 253.99)

p = 0.536

Utilized control group 5th and 95th centiles as reference ranges. Used 5th: 95th group as reference.

Crude OR for CHD in offspring:

Zinc <5th 0.67 (0.24 to 1.87)

Zinc >95th 0.50 (0.17 to 1.46)

aOR (age, maternal residence, folic acid supplement, previous pregnancy) for CHD in offspring:

Zinc <5th 0.69 (0.23 to 2.04)

Zinc >95th 0.56 (0.16 to 1.91)

No difference in zinc levels between cases and controls.

Crude OR and aOR does not provide evidence for increased odds of CHD in offspring with high or low zinc.

Vitamin A

Dilli et al.

Mean ± SD

mg/L

Cases: 692.6 ± 341.4

Minimum 0.55 maximum 1,060

Controls: 749.5 ± 338.6

Minimum 0.15 maximum 1,690

p = .38

Unable to calculate with available data

No difference in vitamin A levels between cases and controls

No definition of reference ranges for deficiency and therefore OR not calculated

Vitamin B12

Dilli et al.

Mean ± SD

ng/L

Cases: 249.7 ± 105.8

Controls: 251.4 ± 87.6

p = .93

Unable to calculate with available data

No difference in vitamin B12 levels between cases and controls

No definition of reference ranges for deficiency and therefore OR not calculated

Verkleij Hagoort et al.

Median (min: max)

ng/L

Cases: 356.46 (111.14 to 815.93)

Controls: 336.13 (120.62 to 1,053.12)

p > .05

Utilized control group < 10th (159 pmol/L) as deficiency definition. Used > 10th group as OR reference

Crude OR for CHD in offspring:

B12 < 10th 1.8 (0.8 to 4)

No difference in vitamin B12 levels between cases and controls

Crude OR does not provide evidence for increased odds of CHD in offspring with low B12

Hobbs et al.

Median (min: max)

ng/L

Cases: 418.20 (94.21 to 957.30)

Controls: 454.50 (100.72 to 1,045.0)

Unadjusted p = .2569

Adjusted p = 0.3953 (age, race, education, income, cigarette use, alcohol consumption, vitamin intake, caffeine intake, interval pregnancy to testing)

No reference ranges. OR for association between case or control status and log transformed B12 concentration

aOR (other biomarkers: folate, homocysteine, methionine, SAH, SAM, adenosine), education, cigarette use, interval pregnancy to testing for CHD in offspring:

B12 1.35 (0.58 to 3.15) p = 0.4875

No difference in vitamin B12 levels between cases and controls

aOR does not provide evidence for increased odds of CHD in offspring in relation to B12

Folate

Dilli et al.

Mean ± SD

nmol/L

Serum folate

Cases: 22.27 ± 13.18

Controls: 22.27 ± 10.45

p = 0.94

Unable to calculate with available data

No difference in serum folate levels between cases and controls

No definition of reference ranges for deficiency and therefore OR not calculated

Verkleij Hagoort et al.

Median (min: max)

nmol/L

Serum folate

Cases: 15 (6.2 to 27.8)

Controls: 14.1 (6.4 to 40.3)

p > .05

RBC folate

Cases: 646 (299 to 1,343)

Controls: 630 (163 to 1,549)

p > .05

Utilized control group < 10th as reference ranges (<10.1 nmol/L serum, <431 nmol/L RBC). Used > 10th group as OR reference

Crude OR for CHD in offspring:

Serum folate<10th 1.3 (0.5 to 3.1)

RBC folate<10th 1.1 (0.4 to 2.6)

Higher levels of serum folate in cases than controls. However, not significant to 5% level when adjusted

aOR does not provide evidence for increased odds of CHD in offspring in relation to plasma folate

Hobbs et al.

Median (min: max)

mg/L

Plasma folate

Cases: 9.6 (1.86 to 30.23)

Controls: 10.66 (3.55 to 40.12)

Unadjusted p = 0.0174

Adjusted p = 0.1681 (age, race, education, income, cigarette use, alcohol consumption, vitamin intake, caffeine intake, interval pregnancy to testing)

No reference ranges. OR for association between case or control status and log transformed plasma folate concentration

aOR (other biomarkers: Folate, homocysteine, methionine, SAH, SAM, adenosine), education, cigarette use, interval pregnancy to testing for CHD in offspring:

Plasma folate 0.89 (0.41 to 1.96) p = 0.7781

No difference in folate levels between cases and controls

aOR does not provide evidence for increased odds of CHD in offspring in relation to B12

a

OR not calculated in original paper, therefore calculated by authors.

TABLE 2

Published reference ranges for micronutrients (Cunningham, 2010)

Micronutrient (unit)Not pregnantSecond trimester
Vitamin A (mg/L)0.2 to 10.35 to 0.44
Vitamin B12 (ng/L)279 to 966130 to 656
Vitamin D (nmol/L)34.94 to 199.6824.96 to 54.91
Ferritin (μg/L)10 to 1502 to 230
Serum folate (nmol/L)12.24 to 40.791.81 to 54.38
RBC folate (nmol/L)339.90 to 1,019.70213.00 to 1876.25
Copper (μg/L)700 to 1,4001,650 to 2,210
Selenium (μg/L)63 to 16075 to 145
Zinc (μg/dL)75 to 12051 to 80

Note: NR ‐ not recorded.

3.3.1

Vitamin D

Three studies assessed vitamin D levels between cases and controls (Dilli et al., 2018; Koster et al., 2018; Mokhtar et al., 2019). All three identified significantly lower levels of vitamin D in cases when compared to control samples. Two studies specified timing of maternal blood sampling (Dilli et al., 2018; Koster et al., 2018). The mean vitamin D levels in both cases and controls reported by Dilli et al., when compared to published reference ranges were classified as deficient.

ORs could not be calculated for this study from available data. Median vitamin D levels reported by Koster et al. for cases and controls were in the normal range for published reference ranges. This robust study design with a large sample size suggested an increased adjusted odds of CHD in vitamin D deficiency (1.82 [1.25 to 2.66]; p = .002). Confounders adjusted for included age, body mass index (BMI), ethnicity and smoking. However, deficiency was defined as <50 nmol/L, a higher value than in published literature (lower reference range 34.94 nmol/L).

Mokhtar et al. did not define timing of maternal blood sampling and as such vitamin D levels could not be compared to published reference ranges. Crude OR suggested no evidence for increased odds of CHD in vitamin D deficiency, defined as <50 nmol/L. However, this study had a small sample size of 50 cases and controls with odds ratios not adjusted for potential confounders.

3.3.2

Vitamin B12

Three studies assessed vitamin B12 levels between cases and controls (Dilli et al., 2018), with all three studies showing no significant difference in B12 levels. The mean vitamin B12 levels reported by Dilli et al. in cases and controls were both deficient when compared to published reference ranges. ORs could not be calculated from available data. The median vitamin B12 levels reported by Verkleij‐Hagoort et al. (2006) in cases and controls were both in the normal range when compared to published reference ranges.

Crude OR did not suggest an increase in odds of CHD in mothers with B12 deficiency. However, deficiency was defined as <159 ng/L which is significantly lower than published definition of deficiency. Therefore, this challenges this finding. The median vitamin B12 levels reported by Hobbs et al. (2005) in cases and controls were both in the normal range when compared to published reference ranges. Adjusted OR did not provide evidence of increased odds of CHD in lower vitamin B12.

However, no references for odds calculation were stipulated.

3.3.3

Folate

Three studies assessed folate levels between cases and controls, with all three studies showing no significant difference in folate levels (Dilli et al., 2018). ORs could not be calculated from available data for Dilli et al. OR presented by Verkleij‐Hagoort et al. and Hobbs et al. did not suggest an increase in odds of CHD in mothers with a lower folate. Dilli et al. and Verkleij‐Hagoort et al. assessed serum folate levels, with the mean or median level for both cases and controls within the normal range when compared to published reference ranges.

No available published reference values are available for plasma folate assessed by Hobbs et al.

3.3.4

Vitamin A

One study assessed vitamin A levels between cases and controls with no significant difference between the two groups (Dilli et al., 2018). The range of vitamin concentrations for both cases and controls were large, with the mean values above the upper end of published reference values for both cases and controls. Assessment was done in a small sample of 50 cases and 50 controls. ORs could not be calculated from available data.

3.3.5

Zinc

Two studies assessed zinc levels between cases and controls (Dilli et al., 2018; Hu et al., 2014). Hu et al. (2014) assessed hair concentrations of zinc. Analysis of hair did not identify any significant difference in levels of zinc between cases and controls. Crude and adjusted OR did not provide evidence for increased odds of CHD in offspring with high or low zinc. Published reference values for hair concentrations are not available and therefore control group 5th and 95th centiles were used as references for deficiency and excess.

Dilli et al. assessed serum concentrations and identified significantly higher levels of zinc in cases than controls. ORs could not be calculated for this study from available data. When compared to published reference ranges, mean zinc concentration of the control group was deficient while the case group was in the normal range. Furthermore, a small sample of 50 cases and 50 controls were assessed. These heterogenous studies test different maternal sample sites with contradictory findings.

3.3.6

Copper

Two studies assessed copper levels between cases and controls (Hu et al., 2014; Ou et al., 2017). Hu et al. assessed hair concentrations of copper, with significantly higher levels of copper in cases than controls. ORs adjusted for age, maternal residence, folic acid supplementation and previous pregnancy suggested an increased odds of CHD in higher copper hair concentrations (5.7 [2.58 to 12.61]). There was no evidence of increased odds of CHD in lower copper hair concentrations. This study was well designed, utilizing the 5th and 95th centiles of the control group copper levels as references for deficiency and excess due to lack of published reference values for hair concentrations.

Ou et al. assessed plasma concentrations of copper, with significantly lower levels of copper in cases than controls. However, crude OR did not provide evidence of increased odds of CHD in offspring of mothers with low copper. When plasma values were compared to published reference ranges, the median level in both cases and controls was deficient. The tertiles of control group data were utilized as reference for ORs and therefore, assessment of CHD risk relative to deficiency is limited. These heterogenous studies test different maternal sample sites with contradictory findings.

3.3.7

Selenium

One study assessed selenium levels between cases and controls (Ou et al., 2017). Lower levels of selenium were present in cases than in controls, with decreased adjusted odds of CHD in offspring with higher selenium levels. However, both cases and controls had higher median selenium levels than normal reference values, with the tertiles of control group utilized as references for OR calculation. While well designed, this limits assessment of CHD risk relative to selenium deficiency.

3.3.8

Ferritin

One study assessed ferritin levels between cases and controls (Yang et al., 2020), with significantly lower levels of ferritin present in cases. However, both cases and controls had ferritin levels within the normal range when compared to published reference ranges. Mixed linear regression modeling adjusting for maternal age, gestational age, residence, education, occupation, parity, passive smoking and folate supplementation suggested lower levels of serum ferritin in cases than controls. There was no definition or assessment of ferritin (iron) deficiency in analysis.

Furthermore, this was a small sample of 50 cases and 100 controls where biochemical analysis was performed.

Source: Micronutrient subgroups Source: Micronutrient subgroups Source: Micronutrient subgroups Source: Micronutrient subgroups Source: Micronutrient subgroups Source: Micronutrient subgroups Source: Micronutrient subgroups Source: Micronutrient subgroups Source: Micronutrient subgroups Source: Micronutrient subgroups Source: Micronutrient subgroups

RESULTS: Confounding variable assessment

Figure 2 summarizes the proportion of studies which accounted for individual confounding variables in their analysis of odds of CHD. Age was the most frequent confounder accounted for in 50% of studies, followed by maternal smoking status, maternal education, parity, folate supplementation and timing of maternal micronutrient sampling in 37.5% of studies. It is therefore clear that across the included studies, unaccounted for confounding variables may bias analyses presented.

FIGURE 2

Confounding variables that were adjusted for in included studies, proportion of studies

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Confounding variable assessment Source: Confounding variable assessment

DISCUSSION: Main findings and interpretation

Assessing the eight micronutrients included in this systematic review, there is not enough evidence to confidently determine if maternal micronutrient deficiency increases the risk of CHD in fetuses. This is exemplified in the small sample sizes included from heterogenous studies, reporting contradictory findings. Studies included were all of case control design. Data from randomized controlled or controlled trials was not available.

Included studies suggested lower levels of vitamin D, selenium and ferritin in cases than controls; no difference in levels of vitamin B12, folate and vitamin A; and contradictory findings for zinc and copper (Dilli et al., 2018; Hobbs et al., 2005; Hu et al., 2014; Koster et al., 2018; Mokhtar et al., 2019; Ou et al., 2017; Verkleij‐Hagoort et al., 2006; Yang et al., 2020). Deficiency is defined as “a shortage of a substance (as vitamins) necessary to health” (Merriam‐Webster, 2021).

Pregnancy is a state of altered physiology and metabolism which can influence laboratory test value ranges (Cunningham, 2010). Reference values are rarely reported for pregnancy. In this systematic review, we compared median or mean micronutrient levels for cases and controls to published reference ranges established by systematic review of literature utilizing the 2.5 to 97.5 centiles as a normal range (Cunningham, 2010). When compared to these published reference ranges, mean or median values reported for cases and controls in studies were often both deficient or both in the normal range.

For vitamin D and vitamin B12 where deficiency was assessed by ORs, deficiency threshold defined in the studies differed from published reference ranges, limiting these findings (Koster et al., 2018; Mokhtar et al., 2019; Verkleij‐Hagoort et al., 2006). Furthermore, published reference ranges are only available for blood samples and not hair (Hu et al., 2014). One study of copper and zinc utilized hair sampling as opposed to blood sampling (Hu et al., 2014). While well designed, it is unclear whether control group references are representative of the population.

This could contribute to the contradictory findings in these micronutrients. Therefore, across the eight micronutrients studied, true assessment of deficiency has not been performed and limits conclusions drawn.

Numerous factors influence micronutrient levels including BMI, age, ethnicity and a number of lifestyle factors such as smoking (Damms‐Machado et al., 2012; Kant & Graubard, 2007; Preston, 1991; Richard & Roussel, 1999). Of the eight papers included, five adjusted for confounders in their analysis (Hobbs et al., 2005; Hu et al., 2014; Koster et al., 2018; Ou et al., 2017; Yang et al., 2020). However, as Figure 2 illustrates, adjustments for confounders were limited with factors such as ethnicity only being recognized in 12.5% of studies.

Furthermore, pregnancy and gestational age are known to influence blood micronutrient levels (Cunningham, 2010). This is particularly important for systematic review given the heterogeneity of timing of sampling in the included studies. Of the included studies, four sampled postnatally, two antenatally and two did not specify timing. However, given the critical sensitive period for cardiac development of 3 to 8 weeks, nutrition in the periconceptual period is likely most relevant (Moore et al., 2020). Studies assessing micronutrient levels and dietary patterns suggest that postnatal assessment of a number of micronutrients including vitamin B12, folate and zinc represents that of the periconceptual period (Cucó et al., 2006; Devine et al., 2000; van Driel et al., 2010).

However, sample sizes were small, with only 30 patients in the direct study of micronutrient levels (van Driel et al., 2010). Furthermore, this was performed in fertility patients, potentially unrepresentative of the general population (van Driel et al., 2010). Therefore, the sample timings in included studies may not accurately represent periconceptual and early pregnancy levels, limiting findings.

Despite these limitations, there remains biological and physiological plausibility for specific micronutrient deficiencies being associated with fetal CHD. Micronutrients are known to play essential roles in cellular signaling, growth and development (McArdle & Ashworth, 1999). Vitamin D deficiency is a significant public health issue, with prevalence reported in 40 to 80% of the pregnant population. Maternal and fetal concentrations increase by up to 200% in the first trimester, with vitamin D acting on gene expression to influence long term health (Kaludjerovic & Vieth, 2010).

Animal models have demonstrated knockdown of the vitamin D receptor is characterized by CHD (Kwon, 2016). Selenium performs biological function within selenoproteins, involved in vast physiological processes including protecting cells from oxidative stress (Labunskyy et al., 2014). Iron deficiency anemia is common in pregnancy, affecting approximately 20% of women in developed countries (Allen, 2000). Animal modeling of iron deficiency and defects in the transferrin receptor have been associated with neural tube and cardiovascular defects in animal models (Andersen et al., 2006; Hoyle et al., 1996).

These associations and biological roles stress the importance of future research in this field.

Source: Main findings and interpretation Source: Main findings and interpretation Source: Main findings and interpretation Source: Main findings and interpretation

What strengths and limitations does the paper describe?

DISCUSSION: What strengths and limitations does the paper describe?

This study was the first to address this topic and performed a robust review with clear inclusion criteria and population definitions. Further comparison to established published reference ranges strengthens the findings. This facilitates objective comparison across studies and illustrates the heterogeneity of results. The use of recognized reference ranges defining deficiency is essential in future studies in this field. However, there are limitations. The inclusion of observational studies introduces uncertainty through their inherent limitations including susceptibility to bias and confounding.

Inclusion and performance of such studies is necessitated in this subject area where controlled studies will not be available. Therefore, comparisons of case and control groups with full recognition of confounders in analysis is key for future research. The heterogeneity of studies including populations, CHD included and timings and methods of sample analysis prevented meta‐analysis. Therefore, the study focused on a narrative synthesis. Utilization of classifications of CHD such as those provided by EUROCAT and increased sample sizes with subgroup analyses could reduce heterogeneity and strengthen future findings (EUROCAT, 2013).

Source: Strengths and limitations

RESULTS

3.1

Literature search

A PRISMA flow chart of included studies is seen in Figure 1. Seven hundred and twenty‐six unique citations were identified after an initial database and reference search. Of these, 691 were excluded after title and abstract screening. The full text of 34 articles were reviewed, with 1 report not retrieved due to journal inaccessibility. A further 26 articles were excluded with reasons outlined in Figure 1, and 8 articles included in the systematic review (Dilli et al., 2018; Hobbs et al., 2005; Hu et al., 2014; Koster et al., 2018; Mokhtar et al., 2019; Ou et al., 2017; Verkleij‐Hagoort et al., 2006; Yang et al., 2020).

FIGURE 1

PRISMA 2020 flow diagram of study identification, screening, inclusion, and exclusion from Page et al. (2021)

Figure image at the original source: open the original paper. This file is not included in this text import.
3.2

General characteristics of studies

The characteristics of the studies included in the review are summarized in Table S1. The review included data from 2,427 pregnancies, of which 1,199 had fetuses affected by CHD. Data was available on maternal levels of 8 micronutrients across studies: vitamin D, vitamin B12, folate, vitamin A, zinc, copper, selenium and ferritin. Studies originated from 5 countries: Turkey, Netherlands (2), United States, China (3), and Egypt. Studies were published in English between 2005 and 2020.

In all but 1 study, maternal micronutrient testing was through venous blood analysis of serum or plasma. One study including copper and zinc micronutrients performed testing of maternal hair. Of the six studies reporting timing of sampling, four assessed micronutrient levels postnatally. Two studies assessed levels during pregnancy between 17 weeks and delivery. In three studies CHD diagnosis was performed antenatally, four studies performed postnatal diagnosis and one study included both with cases identified through a state registry. Each study had varying proportions of diverse CHD.

The range of included studies with heterogenous micronutrient assessment, sampling technique, sample timing and CHD diagnosis and subtypes precluded quantitative synthesis of data.

3.3

Micronutrient subgroups

Table 1 summarizes differences in micronutrient levels between cases and control groups for the seven micronutrients included and ORs where calculated. Table 2 summarizes published reference ranges for micronutrients for nonpregnant and second trimester pregnant women (Cunningham, 2010).

TABLE 1

Assessment of micronutrient levels and odds ratios in included studies (NR ‐ not recorded) (Dilli et al., 2018; Hobbs et al., 2005; Hu et al., 2014; Koster et al., 2018; Mokhtar et al., 2019; Ou et al., 2017; Verkleij‐Hagoort et al., 2006; Yang et al., 2020)

MicronutrientRaw dataOdds ratiosEffect direction
Vitamin D

Dilli et al.

Mean ± SD

nmol/L

Cases: 26.7 ± 18.0

Controls: 34.4 ± 16.7

p = .02

Unable to calculate with available data

Lower levels of vitamin D in cases than controls

No definition of reference ranges for deficiency and therefore OR not calculated

Koster et al.

Median (IQR)

nmol/L

Cases: 57.8 (41.6 to 78.7)

Controls: 65.8 (40.5 to 86.6)

p = .02

Vitamin D deficient < 50 nmol/L, moderate 50 to 75 nmol/L. Utilizing adequate vitamin D group (>75 nmol/L) as reference

Crude OR for CHD in offspring:

Deficient 1.63 (1.15 to 2.32) p = .006

Moderate 1.60 (1.12 to 2.28) p = .006

aOR (age, BMI, ethnicity, smoking) for CHD in offspring:

Deficient 1.82 (1.25 to 2.66) p = .002

Moderate 1.58 (1.11 to 2.26) p = .002

Lower levels of vitamin D in cases than controls

Crude and adjusted OR suggest increased odds of CHD in offspring with vitamin D deficiency and moderate levels

Mokhtar et al.

Median (IQR)

nmol/L

Cases: 26 (10: NR)

Controls: 37 (16 to 76)

p = .002

Vitamin D deficient < 50 nmol/L, moderate 50 to 75 nmol/L. Utilizing adequate vitamin D group (>75 nmol/L) as reference a

Crude OR for CHD in offspring:

Deficient 2.48 (0.58 to 10.70) p = .22

Moderate 1.09 (0.20 to 6.01) p = .92

Lower levels of vitamin D in cases than controls

Crude OR does not provide evidence for increased odds of CHD in offspring with vitamin D deficiency or moddilli erate levels

Ferritin

Yang et al.

Median (IQR)

μg/L

Cases: 14.3 (9.7 to 30.3)

Controls 21.6 (14.1 to 39.9)

p = .003

Mixed linear regression model with control group as reference. No definitions of deficiency

Unadjusted expB:

Ferritin 0.71 (0.56 to 0.89) p = .003

Adjusted expB (maternal age, gestational age, residence, education, occupation, parity, passive smoking, folate supplement):

Ferritin 0.69 (0.54 to 0.88) p = .001

Lower levels of ferritin in cases than controls

Unadjusted and adjusted expB suggest lower levels of serum ferritin in case group prior to delivery than control group

Copper

Hu et al.

Median (IQR)

μg/g

Cases: 12.79 (8.96 to 17.25)

Controls: 8.77 (7.56 to 10.91)

p < .001

Utilized control group 5th and 95th centiles as reference ranges. Used 5th: 95th group as reference

Crude OR for CHD in offspring:

Copper <5th 0.36 (0.1 to 1.36)

Copper >95th 5.38 (2.64 to 10.95)

aOR (age, maternal residence, folic acid supplement, previous pregnancy) for CHD in offspring:

Copper <5th 0.63 (0.15 to 2.73)

Copper >95th 5.7 (2.58 to 12.61)

Higher levels of copper in cases than controls

Crude OR and aOR does not provide evidence for increased odds of CHD in offspring with low copper. Suggest high copper levels in case group compared to controls

Ou et al.

Median (IQR)

μg/L

Cases: 838.38 (778.90 to 936.98)

Controls: 896.56 (817.62 to 979.44)

p = .02

Utilized control group tertiles as reference ranges. Used low tertile as reference. Multivariable multielement logistic regression

aOR (age, parity, education, newborn gender, migration, folic acid/multivitamin, smoking, pre‐pregnancy BMI, gestation sample) for CHD in offspring:

Copper middle tertile 0.57 (0.22 to 1.47)

Copper high Tertile 0.77 (0.31 to 1.89)

Utilized control group tertiles as reference ranges. Used middle tertile as reference. a

Crude OR for CHD in offspring:

Copper low Tertile 1.91 (0.996 to 3.661) p = .0514

Lower levels of copper in cases than controls

aOR does not provide evidence for increased odds of CHD in offspring with high copper

Crude OR does not provide evidence for increased odds of CHD in offspring with low copper

Selenium

Ou et al.

Median (IQR)

μg/L

Cases: 172.90 (153.87 to 192.23)

Controls: 186.47 (172.45 to 207.34)

p < .001

Utilized control group tertiles as reference ranges. Used low tertile as reference. Multivariable multielement logistic regression

aOR (age, parity, education, newborn gender, migration, folic acid/multivitamin, smoking, pre‐pregnancy BMI, gestation sample) for CHD in offspring:

Selenium middle tertile 0.55 (0.22 to 1.38)

Selenium high tertile 0.25 (0.08 to 0.77)

Utilized control group tertiles as reference ranges. Used middle tertile as reference a

Crude OR for CHD in offspring:

Selenium low tertile 2.17 (1.15 to 4.11) p = .0171

Lower levels of selenium in cases than controls

aOR suggest decreased odds of CHD in offspring with higher selenium

Crude OR suggest increased odds of CHD in offspring with lower selenium

Zinc

Dilli et al.

Mean ± SD

μg/DL

Cases: 86.0 ± 15.3

Controls: 69.4 ± 15.1

p < .001

Unable to calculate with available data

Higher levels of zinc in cases than controls

No definition of reference ranges for deficiency and therefore OR not calculated

Hu et al.

Median (IQR)

μg/g

Cases: 180.01 (144.59 to 264.39)

Controls: 166.44 (142.02 to 253.99)

p = 0.536

Utilized control group 5th and 95th centiles as reference ranges. Used 5th: 95th group as reference.

Crude OR for CHD in offspring:

Zinc <5th 0.67 (0.24 to 1.87)

Zinc >95th 0.50 (0.17 to 1.46)

aOR (age, maternal residence, folic acid supplement, previous pregnancy) for CHD in offspring:

Zinc <5th 0.69 (0.23 to 2.04)

Zinc >95th 0.56 (0.16 to 1.91)

No difference in zinc levels between cases and controls.

Crude OR and aOR does not provide evidence for increased odds of CHD in offspring with high or low zinc.

Vitamin A

Dilli et al.

Mean ± SD

mg/L

Cases: 692.6 ± 341.4

Minimum 0.55 maximum 1,060

Controls: 749.5 ± 338.6

Minimum 0.15 maximum 1,690

p = .38

Unable to calculate with available data

No difference in vitamin A levels between cases and controls

No definition of reference ranges for deficiency and therefore OR not calculated

Vitamin B12

Dilli et al.

Mean ± SD

ng/L

Cases: 249.7 ± 105.8

Controls: 251.4 ± 87.6

p = .93

Unable to calculate with available data

No difference in vitamin B12 levels between cases and controls

No definition of reference ranges for deficiency and therefore OR not calculated

Verkleij Hagoort et al.

Median (min: max)

ng/L

Cases: 356.46 (111.14 to 815.93)

Controls: 336.13 (120.62 to 1,053.12)

p > .05

Utilized control group < 10th (159 pmol/L) as deficiency definition. Used > 10th group as OR reference

Crude OR for CHD in offspring:

B12 < 10th 1.8 (0.8 to 4)

No difference in vitamin B12 levels between cases and controls

Crude OR does not provide evidence for increased odds of CHD in offspring with low B12

Hobbs et al.

Median (min: max)

ng/L

Cases: 418.20 (94.21 to 957.30)

Controls: 454.50 (100.72 to 1,045.0)

Unadjusted p = .2569

Adjusted p = 0.3953 (age, race, education, income, cigarette use, alcohol consumption, vitamin intake, caffeine intake, interval pregnancy to testing)

No reference ranges. OR for association between case or control status and log transformed B12 concentration

aOR (other biomarkers: folate, homocysteine, methionine, SAH, SAM, adenosine), education, cigarette use, interval pregnancy to testing for CHD in offspring:

B12 1.35 (0.58 to 3.15) p = 0.4875

No difference in vitamin B12 levels between cases and controls

aOR does not provide evidence for increased odds of CHD in offspring in relation to B12

Folate

Dilli et al.

Mean ± SD

nmol/L

Serum folate

Cases: 22.27 ± 13.18

Controls: 22.27 ± 10.45

p = 0.94

Unable to calculate with available data

No difference in serum folate levels between cases and controls

No definition of reference ranges for deficiency and therefore OR not calculated

Verkleij Hagoort et al.

Median (min: max)

nmol/L

Serum folate

Cases: 15 (6.2 to 27.8)

Controls: 14.1 (6.4 to 40.3)

p > .05

RBC folate

Cases: 646 (299 to 1,343)

Controls: 630 (163 to 1,549)

p > .05

Utilized control group < 10th as reference ranges (<10.1 nmol/L serum, <431 nmol/L RBC). Used > 10th group as OR reference

Crude OR for CHD in offspring:

Serum folate<10th 1.3 (0.5 to 3.1)

RBC folate<10th 1.1 (0.4 to 2.6)

Higher levels of serum folate in cases than controls. However, not significant to 5% level when adjusted

aOR does not provide evidence for increased odds of CHD in offspring in relation to plasma folate

Hobbs et al.

Median (min: max)

mg/L

Plasma folate

Cases: 9.6 (1.86 to 30.23)

Controls: 10.66 (3.55 to 40.12)

Unadjusted p = 0.0174

Adjusted p = 0.1681 (age, race, education, income, cigarette use, alcohol consumption, vitamin intake, caffeine intake, interval pregnancy to testing)

No reference ranges. OR for association between case or control status and log transformed plasma folate concentration

aOR (other biomarkers: Folate, homocysteine, methionine, SAH, SAM, adenosine), education, cigarette use, interval pregnancy to testing for CHD in offspring:

Plasma folate 0.89 (0.41 to 1.96) p = 0.7781

No difference in folate levels between cases and controls

aOR does not provide evidence for increased odds of CHD in offspring in relation to B12

a

OR not calculated in original paper, therefore calculated by authors.

TABLE 2

Published reference ranges for micronutrients (Cunningham, 2010)

Micronutrient (unit)Not pregnantSecond trimester
Vitamin A (mg/L)0.2 to 10.35 to 0.44
Vitamin B12 (ng/L)279 to 966130 to 656
Vitamin D (nmol/L)34.94 to 199.6824.96 to 54.91
Ferritin (μg/L)10 to 1502 to 230
Serum folate (nmol/L)12.24 to 40.791.81 to 54.38
RBC folate (nmol/L)339.90 to 1,019.70213.00 to 1876.25
Copper (μg/L)700 to 1,4001,650 to 2,210
Selenium (μg/L)63 to 16075 to 145
Zinc (μg/dL)75 to 12051 to 80

Note: NR ‐ not recorded.

3.3.1
Vitamin D

Three studies assessed vitamin D levels between cases and controls (Dilli et al., 2018; Koster et al., 2018; Mokhtar et al., 2019). All three identified significantly lower levels of vitamin D in cases when compared to control samples. Two studies specified timing of maternal blood sampling (Dilli et al., 2018; Koster et al., 2018). The mean vitamin D levels in both cases and controls reported by Dilli et al., when compared to published reference ranges were classified as deficient.

ORs could not be calculated for this study from available data. Median vitamin D levels reported by Koster et al. for cases and controls were in the normal range for published reference ranges. This robust study design with a large sample size suggested an increased adjusted odds of CHD in vitamin D deficiency (1.82 [1.25 to 2.66]; p = .002). Confounders adjusted for included age, body mass index (BMI), ethnicity and smoking. However, deficiency was defined as <50 nmol/L, a higher value than in published literature (lower reference range 34.94 nmol/L).

Mokhtar et al. did not define timing of maternal blood sampling and as such vitamin D levels could not be compared to published reference ranges. Crude OR suggested no evidence for increased odds of CHD in vitamin D deficiency, defined as <50 nmol/L. However, this study had a small sample size of 50 cases and controls with odds ratios not adjusted for potential confounders.

3.3.2
Vitamin B12

Three studies assessed vitamin B12 levels between cases and controls (Dilli et al., 2018), with all three studies showing no significant difference in B12 levels. The mean vitamin B12 levels reported by Dilli et al. in cases and controls were both deficient when compared to published reference ranges. ORs could not be calculated from available data. The median vitamin B12 levels reported by Verkleij‐Hagoort et al. (2006) in cases and controls were both in the normal range when compared to published reference ranges.

Crude OR did not suggest an increase in odds of CHD in mothers with B12 deficiency. However, deficiency was defined as <159 ng/L which is significantly lower than published definition of deficiency. Therefore, this challenges this finding. The median vitamin B12 levels reported by Hobbs et al. (2005) in cases and controls were both in the normal range when compared to published reference ranges. Adjusted OR did not provide evidence of increased odds of CHD in lower vitamin B12.

However, no references for odds calculation were stipulated.

3.3.3
Folate

Three studies assessed folate levels between cases and controls, with all three studies showing no significant difference in folate levels (Dilli et al., 2018). ORs could not be calculated from available data for Dilli et al. OR presented by Verkleij‐Hagoort et al. and Hobbs et al. did not suggest an increase in odds of CHD in mothers with a lower folate. Dilli et al. and Verkleij‐Hagoort et al. assessed serum folate levels, with the mean or median level for both cases and controls within the normal range when compared to published reference ranges.

No available published reference values are available for plasma folate assessed by Hobbs et al.

3.3.4
Vitamin A

One study assessed vitamin A levels between cases and controls with no significant difference between the two groups (Dilli et al., 2018). The range of vitamin concentrations for both cases and controls were large, with the mean values above the upper end of published reference values for both cases and controls. Assessment was done in a small sample of 50 cases and 50 controls. ORs could not be calculated from available data.

3.3.5
Zinc

Two studies assessed zinc levels between cases and controls (Dilli et al., 2018; Hu et al., 2014). Hu et al. (2014) assessed hair concentrations of zinc. Analysis of hair did not identify any significant difference in levels of zinc between cases and controls. Crude and adjusted OR did not provide evidence for increased odds of CHD in offspring with high or low zinc. Published reference values for hair concentrations are not available and therefore control group 5th and 95th centiles were used as references for deficiency and excess.

Dilli et al. assessed serum concentrations and identified significantly higher levels of zinc in cases than controls. ORs could not be calculated for this study from available data. When compared to published reference ranges, mean zinc concentration of the control group was deficient while the case group was in the normal range. Furthermore, a small sample of 50 cases and 50 controls were assessed. These heterogenous studies test different maternal sample sites with contradictory findings.

3.3.6
Copper

Two studies assessed copper levels between cases and controls (Hu et al., 2014; Ou et al., 2017). Hu et al. assessed hair concentrations of copper, with significantly higher levels of copper in cases than controls. ORs adjusted for age, maternal residence, folic acid supplementation and previous pregnancy suggested an increased odds of CHD in higher copper hair concentrations (5.7 [2.58 to 12.61]). There was no evidence of increased odds of CHD in lower copper hair concentrations. This study was well designed, utilizing the 5th and 95th centiles of the control group copper levels as references for deficiency and excess due to lack of published reference values for hair concentrations.

Ou et al. assessed plasma concentrations of copper, with significantly lower levels of copper in cases than controls. However, crude OR did not provide evidence of increased odds of CHD in offspring of mothers with low copper. When plasma values were compared to published reference ranges, the median level in both cases and controls was deficient. The tertiles of control group data were utilized as reference for ORs and therefore, assessment of CHD risk relative to deficiency is limited. These heterogenous studies test different maternal sample sites with contradictory findings.

3.3.7
Selenium

One study assessed selenium levels between cases and controls (Ou et al., 2017). Lower levels of selenium were present in cases than in controls, with decreased adjusted odds of CHD in offspring with higher selenium levels. However, both cases and controls had higher median selenium levels than normal reference values, with the tertiles of control group utilized as references for OR calculation. While well designed, this limits assessment of CHD risk relative to selenium deficiency.

3.3.8
Ferritin

One study assessed ferritin levels between cases and controls (Yang et al., 2020), with significantly lower levels of ferritin present in cases. However, both cases and controls had ferritin levels within the normal range when compared to published reference ranges. Mixed linear regression modeling adjusting for maternal age, gestational age, residence, education, occupation, parity, passive smoking and folate supplementation suggested lower levels of serum ferritin in cases than controls. There was no definition or assessment of ferritin (iron) deficiency in analysis.

Furthermore, this was a small sample of 50 cases and 100 controls where biochemical analysis was performed.

3.4

Confounding variable assessment

Figure 2 summarizes the proportion of studies which accounted for individual confounding variables in their analysis of odds of CHD. Age was the most frequent confounder accounted for in 50% of studies, followed by maternal smoking status, maternal education, parity, folate supplementation and timing of maternal micronutrient sampling in 37.5% of studies. It is therefore clear that across the included studies, unaccounted for confounding variables may bias analyses presented.

FIGURE 2

Confounding variables that were adjusted for in included studies, proportion of studies

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: RESULTS Source: RESULTS Source: RESULTS Source: RESULTS

CONCLUSION

In conclusion, there is not enough evidence to confidently determine if maternal micronutrient deficiency increases the risk of CHD in fetuses. Further studies are required with prospective or nested case control design utilizing established micronutrient reference ranges ideally collecting samples in pregnancy and postnatally. The UK‐based Surgical‐PEARL (Surgical Paediatric congEnital Anomalies Registry with Long term follow‐up) multicenter cohort study has commenced recruitment in 2022 (https://www.isrctn.com/ISRCTN12557586). This will recruit fetuses with congenital anomalies potentially requiring surgery and their biological mothers and fathers at the time of diagnosis, collecting routine clinical and imaging data, postnatal surgical data and a range of fetal, childhood and parental biosamples.

Through resources such as this and others, we aim to establish a greater evidence base to robustly answer this question.

Source: CONCLUSION
Authors’ abstract

Abstract

Background

Congenital anomalies affect over 2% of pregnancies, with congenital heart disease (CHD) the most common. Understanding of causal factors is limited. Micronutrients are essential trace elements with key roles in growth and development. We aimed to investigate whether maternal micronutrient deficiencies increase the risk of fetal CHD through systematic review of published literature.

Method

We performed a systematic review registered at PROSPERO as CRD42021276699. Ovid‐MEDLINE, Ovid‐EMBASE, and Cochrane Library were searched from their inception until September 7, 2021. Case control trials were included with a population of biological mothers of fetuses with and without CHD. The exposure was maternal micronutrient level measured in pregnancy or the postpartum period. Data extraction was performed by one author and checked by a second. Risk of bias assessment was performed according to the Scottish Intercollegiate Guidelines Network guidance.

We performed a narrative synthesis for analysis.

Results

726 articles were identified of which 8 met our inclusion criteria. Final analysis incorporated data from 2,427 pregnancies, 1,199 of which were complicated by fetal CHD assessing 8 maternal micronutrients: vitamin D, vitamin B12, folate, vitamin A, zinc, copper, selenium, and ferritin. Studies were heterogenous with limited sample sizes and differing methods and timing of maternal micronutrient sampling. Definitions of deficiency varied and differed from published literature. Published results were contradictory.

Conclusion

There is not enough evidence to confidently conclude if maternal micronutrient deficiencies increase the risk of fetal CHD. Further large‐scale prospective study is required to answer this question.

Read the full paper
1

INTRODUCTION

Congenital anomalies occur in approximately 1:50 pregnancies. Around 30% are congenital heart disease (CHD), representing the most prevalent congenital anomaly (Public Health England, 2019). CHD is generally defined as a “gross structural abnormality of the heart or intrathoracic great vessels present at birth that is actually or potentially of functional significance (Mitchell et al., 1971).” The most common CHD are ventricular septal defects, atrial septal defects, transposition of the great vessels, patent ductus arteriosus (PDA) and tetralogy of Fallot (Suluba et al., 2020).

As PDA is physiological at birth, the EUROCAT congenital anomaly registry classifies PDA as CHD if persistent 6 months following birth or requiring interventional closure (EUROCAT, 2013). The potential causal molecular, genetic and environmental risk factors remain poorly understood. Approximately 20% of cases can be attributed to genetic, chromosomal or teratogenic causes. The remaining 80% are likely multifactorial including genetic and environmental factors (Blue et al., 2012). Congenital anomalies remain a leading cause of neonatal, infant and childhood death (Petrini et al., 2002).

Patients with CHD often require multiple and complex surgeries with long term medical therapies and follow up. These can involve significant morbidity, long term mortality and substantial cost (Tennant et al., 2010). Primary prevention of CHD would significantly reduce these patient and clinical burdens (Botto & Correa, 2003). However, this requires a greater understanding of causative factors in CHD.

From Day 18 of human embryonic development, the endocardial progenitor cells form heart tubes which ultimately fuse, fold, loop and septate to form the embryonic heart. The heart beats from Day 22, with the critical sensitive period for cardiovascular development generally recognized as between Weeks 3 and 8 of embryonic development (Moore et al., 2020). These processes are under the control of a number of transcription factors, genes and signaling pathways all influenced by genetic and environmental factors (Suluba et al., 2020).

Micronutrients are essential trace elements and vitamins (Shenkin, 2006). Vitamin and micronutrient supplementation in pregnancy is recommended by the Royal College of Obstetricians and Gynecologists (RCOG) and National Institute for Health and Care Excellence (NICE) in the United Kingdom. These include folate before pregnancy and throughout the first 12 weeks predominantly to reduce the risk of neural tube defects and vitamin D to improve growth and reduce deficiency in neonates (NICE, 2014, 2017; RCOG, 2014). Micronutrients play essential roles in intracellular and cellular signaling and growth, and as such facilitate development.

Deficiencies may arise secondary to dietary and physiological factors. Animal studies assessing deficiencies have shown increased rates of congenital anomalies (McArdle & Ashworth, 1999). Studies of CHD in animal models show maternal micronutrient deficiencies including iron and vitamin A lead to increased rates in offspring (Joshi et al., 2020; Kalisch‐Smith et al., 2021). Assessment in these models suggests alterations in signaling pathways including retinoic acid signaling or epigenetic modifications potentially drive pathogenesis. This can be prevented through micronutrient administration (Joshi et al., 2020; Kalisch‐Smith et al., 2021).

Systematic review and meta‐analyses of folate and multivitamin supplementation in pregnancy and the periconceptual period have illustrated reductions in CHD and cardiovascular anomalies, neural tube defects, limb defects, orofacial clefts and urinary tract anomalies in human fetuses (Botto et al., 2004; Feng et al., 2015; Ingrid Goh et al., 2006). However, the included observational studies largely assess supplementation and do not ascertain maternal micronutrient levels.

To our knowledge, a systematic review of maternal micronutrient deficiencies in CHD has not been undertaken previously. We therefore aim to critically appraise available literature to address the question of whether maternal micronutrient deficiencies increase the risk of fetal CHD.

2

METHODS

2.1

Eligibility criteria

2.1.1
Study design

The overarching question addressed in this systematic review was do maternal micronutrient deficiencies increase the risk of fetal CHD? Observational studies were included. It was not anticipated that data from randomized control trials or controlled trials would be available. Case series and case reports were excluded due to high risk of bias.

2.1.2
Population

The target population was pregnant biological mothers of fetuses. Studies including surrogate mothers or pregnancies with egg donation were excluded due to the potential influence of micronutrient levels in the donor or surrogate. The exposure was maternal micronutrient level measured through serum or hair analysis in pregnancy or the postpartum period. Micronutrients in included studies were vitamin A, vitamin B 12, vitamin D, folate, iron, selenium, copper, and zinc.

2.1.3
Outcomes

The outcome assessed was a fetus, neonate or child with CHD. CHD was diagnosed antenatally though fetal echocardiography or postnatally through echocardiography, clinical assessment, cardiac catheterization or surgery.

2.2

Information sources and search strategy

This systematic review protocol was registered at PROSPERO (registration number CRD42021276699). We used the Preferred Reporting Items for Systematic review and Meta‐Analysis (PRISMA) 2020 checklist to develop this systematic review (PRISMA, 2020). A systematic literature search of electronic databases MEDLINE (via OVID), EMBASE (via OVID) and the Cochrane library was conducted to identify relevant studies published between the beginning of each database and September 7, 2021 without language restrictions. We also manually screened reference lists of included studies to identify any additional relevant literature.

A detailed search strategy for each database is outlined in Figure S1. The search strategy was developed around the MeSH descriptors: exp[heart defects, congenital], [micronutrients], [vitamins], [deficiency diseases], exp[avitaminosis]; and the key terms: [congenital heart disease*.tw.], [congenital cardiac disease*.tw.], [congenital heart anomal*.tw.], [congenital cardiac anomal*.tw.], [maternal vitamin*.tw.], [maternal micronutrient*.tw.], [maternal zinc.tw.], [maternal copper.tw.], [maternal iron.tw.] and [maternal fol*.tw.].

2.3

Study selection, data extraction and risk of bias assessment

Two authors (SM and CS) independently screened the titles and abstracts to exclude publications that did not meet the inclusion criteria. Any discrepancies were discussed. After selecting studies for inclusion, data extraction was performed by SM and checked by CS into a prior agreed form. Data extracted included author, year of publication, country of origin, study design, inclusion and exclusion criteria, case and control matching data, micronutrients analyzed, source and timing and CHD diagnosis and analysis. Information on confounding variables and adjusted data was collected.

Risk of bias assessment was assessed by SM and CS utilizing the Scottish Intercollegiate Guidelines Network (SIGN) case control study checklist and associated guidance notes (SIGN, 2012). This facilitates assessment of subject selection, exposure assessment, confounding and statistical analysis. Studies are assessed overall as high quality (++), acceptable (+) or unacceptable. Unacceptable studies were excluded from analysis due to high risk of bias.

2.4

Data synthesis

Results from studies were summarized with a narrative synthesis including summary tables due to the diversity of the included studies. Quantitative synthesis of data was not performed due to the heterogeneity of studies. Analysis was stratified by micronutrient subgroups and micronutrient levels and crude and adjusted odds ratios (OR) were presented. Where possible, if not presented in the primary study, crude ORs were calculated by the study authors. Micronutrients levels were converted into the same unit for each study to allow for direct comparison.

Published micronutrient reference ranges in pregnancy were used to define deficiency to further aid study comparisons (Cunningham, 2010).

3

RESULTS

3.1

Literature search

A PRISMA flow chart of included studies is seen in Figure 1. Seven hundred and twenty‐six unique citations were identified after an initial database and reference search. Of these, 691 were excluded after title and abstract screening. The full text of 34 articles were reviewed, with 1 report not retrieved due to journal inaccessibility. A further 26 articles were excluded with reasons outlined in Figure 1, and 8 articles included in the systematic review (Dilli et al., 2018; Hobbs et al., 2005; Hu et al., 2014; Koster et al., 2018; Mokhtar et al., 2019; Ou et al., 2017; Verkleij‐Hagoort et al., 2006; Yang et al., 2020).

FIGURE 1

PRISMA 2020 flow diagram of study identification, screening, inclusion, and exclusion from Page et al. (2021)

Figure image at the original source: open the original paper. This file is not included in this text import.
3.2

General characteristics of studies

The characteristics of the studies included in the review are summarized in Table S1. The review included data from 2,427 pregnancies, of which 1,199 had fetuses affected by CHD. Data was available on maternal levels of 8 micronutrients across studies: vitamin D, vitamin B12, folate, vitamin A, zinc, copper, selenium and ferritin. Studies originated from 5 countries: Turkey, Netherlands (2), United States, China (3), and Egypt. Studies were published in English between 2005 and 2020.

In all but 1 study, maternal micronutrient testing was through venous blood analysis of serum or plasma. One study including copper and zinc micronutrients performed testing of maternal hair. Of the six studies reporting timing of sampling, four assessed micronutrient levels postnatally. Two studies assessed levels during pregnancy between 17 weeks and delivery. In three studies CHD diagnosis was performed antenatally, four studies performed postnatal diagnosis and one study included both with cases identified through a state registry. Each study had varying proportions of diverse CHD.

The range of included studies with heterogenous micronutrient assessment, sampling technique, sample timing and CHD diagnosis and subtypes precluded quantitative synthesis of data.

3.3

Micronutrient subgroups

Table 1 summarizes differences in micronutrient levels between cases and control groups for the seven micronutrients included and ORs where calculated. Table 2 summarizes published reference ranges for micronutrients for nonpregnant and second trimester pregnant women (Cunningham, 2010).

TABLE 1

Assessment of micronutrient levels and odds ratios in included studies (NR ‐ not recorded) (Dilli et al., 2018; Hobbs et al., 2005; Hu et al., 2014; Koster et al., 2018; Mokhtar et al., 2019; Ou et al., 2017; Verkleij‐Hagoort et al., 2006; Yang et al., 2020)

MicronutrientRaw dataOdds ratiosEffect direction
Vitamin D

Dilli et al.

Mean ± SD

nmol/L

Cases: 26.7 ± 18.0

Controls: 34.4 ± 16.7

p = .02

Unable to calculate with available data

Lower levels of vitamin D in cases than controls

No definition of reference ranges for deficiency and therefore OR not calculated

Koster et al.

Median (IQR)

nmol/L

Cases: 57.8 (41.6 to 78.7)

Controls: 65.8 (40.5 to 86.6)

p = .02

Vitamin D deficient < 50 nmol/L, moderate 50 to 75 nmol/L. Utilizing adequate vitamin D group (>75 nmol/L) as reference

Crude OR for CHD in offspring:

Deficient 1.63 (1.15 to 2.32) p = .006

Moderate 1.60 (1.12 to 2.28) p = .006

aOR (age, BMI, ethnicity, smoking) for CHD in offspring:

Deficient 1.82 (1.25 to 2.66) p = .002

Moderate 1.58 (1.11 to 2.26) p = .002

Lower levels of vitamin D in cases than controls

Crude and adjusted OR suggest increased odds of CHD in offspring with vitamin D deficiency and moderate levels

Mokhtar et al.

Median (IQR)

nmol/L

Cases: 26 (10: NR)

Controls: 37 (16 to 76)

p = .002

Vitamin D deficient < 50 nmol/L, moderate 50 to 75 nmol/L. Utilizing adequate vitamin D group (>75 nmol/L) as reference a

Crude OR for CHD in offspring:

Deficient 2.48 (0.58 to 10.70) p = .22

Moderate 1.09 (0.20 to 6.01) p = .92

Lower levels of vitamin D in cases than controls

Crude OR does not provide evidence for increased odds of CHD in offspring with vitamin D deficiency or moddilli erate levels

Ferritin

Yang et al.

Median (IQR)

μg/L

Cases: 14.3 (9.7 to 30.3)

Controls 21.6 (14.1 to 39.9)

p = .003

Mixed linear regression model with control group as reference. No definitions of deficiency

Unadjusted expB:

Ferritin 0.71 (0.56 to 0.89) p = .003

Adjusted expB (maternal age, gestational age, residence, education, occupation, parity, passive smoking, folate supplement):

Ferritin 0.69 (0.54 to 0.88) p = .001

Lower levels of ferritin in cases than controls

Unadjusted and adjusted expB suggest lower levels of serum ferritin in case group prior to delivery than control group

Copper

Hu et al.

Median (IQR)

μg/g

Cases: 12.79 (8.96 to 17.25)

Controls: 8.77 (7.56 to 10.91)

p < .001

Utilized control group 5th and 95th centiles as reference ranges. Used 5th: 95th group as reference

Crude OR for CHD in offspring:

Copper <5th 0.36 (0.1 to 1.36)

Copper >95th 5.38 (2.64 to 10.95)

aOR (age, maternal residence, folic acid supplement, previous pregnancy) for CHD in offspring:

Copper <5th 0.63 (0.15 to 2.73)

Copper >95th 5.7 (2.58 to 12.61)

Higher levels of copper in cases than controls

Crude OR and aOR does not provide evidence for increased odds of CHD in offspring with low copper. Suggest high copper levels in case group compared to controls

Ou et al.

Median (IQR)

μg/L

Cases: 838.38 (778.90 to 936.98)

Controls: 896.56 (817.62 to 979.44)

p = .02

Utilized control group tertiles as reference ranges. Used low tertile as reference. Multivariable multielement logistic regression

aOR (age, parity, education, newborn gender, migration, folic acid/multivitamin, smoking, pre‐pregnancy BMI, gestation sample) for CHD in offspring:

Copper middle tertile 0.57 (0.22 to 1.47)

Copper high Tertile 0.77 (0.31 to 1.89)

Utilized control group tertiles as reference ranges. Used middle tertile as reference. a

Crude OR for CHD in offspring:

Copper low Tertile 1.91 (0.996 to 3.661) p = .0514

Lower levels of copper in cases than controls

aOR does not provide evidence for increased odds of CHD in offspring with high copper

Crude OR does not provide evidence for increased odds of CHD in offspring with low copper

Selenium

Ou et al.

Median (IQR)

μg/L

Cases: 172.90 (153.87 to 192.23)

Controls: 186.47 (172.45 to 207.34)

p < .001

Utilized control group tertiles as reference ranges. Used low tertile as reference. Multivariable multielement logistic regression

aOR (age, parity, education, newborn gender, migration, folic acid/multivitamin, smoking, pre‐pregnancy BMI, gestation sample) for CHD in offspring:

Selenium middle tertile 0.55 (0.22 to 1.38)

Selenium high tertile 0.25 (0.08 to 0.77)

Utilized control group tertiles as reference ranges. Used middle tertile as reference a

Crude OR for CHD in offspring:

Selenium low tertile 2.17 (1.15 to 4.11) p = .0171

Lower levels of selenium in cases than controls

aOR suggest decreased odds of CHD in offspring with higher selenium

Crude OR suggest increased odds of CHD in offspring with lower selenium

Zinc

Dilli et al.

Mean ± SD

μg/DL

Cases: 86.0 ± 15.3

Controls: 69.4 ± 15.1

p < .001

Unable to calculate with available data

Higher levels of zinc in cases than controls

No definition of reference ranges for deficiency and therefore OR not calculated

Hu et al.

Median (IQR)

μg/g

Cases: 180.01 (144.59 to 264.39)

Controls: 166.44 (142.02 to 253.99)

p = 0.536

Utilized control group 5th and 95th centiles as reference ranges. Used 5th: 95th group as reference.

Crude OR for CHD in offspring:

Zinc <5th 0.67 (0.24 to 1.87)

Zinc >95th 0.50 (0.17 to 1.46)

aOR (age, maternal residence, folic acid supplement, previous pregnancy) for CHD in offspring:

Zinc <5th 0.69 (0.23 to 2.04)

Zinc >95th 0.56 (0.16 to 1.91)

No difference in zinc levels between cases and controls.

Crude OR and aOR does not provide evidence for increased odds of CHD in offspring with high or low zinc.

Vitamin A

Dilli et al.

Mean ± SD

mg/L

Cases: 692.6 ± 341.4

Minimum 0.55 maximum 1,060

Controls: 749.5 ± 338.6

Minimum 0.15 maximum 1,690

p = .38

Unable to calculate with available data

No difference in vitamin A levels between cases and controls

No definition of reference ranges for deficiency and therefore OR not calculated

Vitamin B12

Dilli et al.

Mean ± SD

ng/L

Cases: 249.7 ± 105.8

Controls: 251.4 ± 87.6

p = .93

Unable to calculate with available data

No difference in vitamin B12 levels between cases and controls

No definition of reference ranges for deficiency and therefore OR not calculated

Verkleij Hagoort et al.

Median (min: max)

ng/L

Cases: 356.46 (111.14 to 815.93)

Controls: 336.13 (120.62 to 1,053.12)

p > .05

Utilized control group < 10th (159 pmol/L) as deficiency definition. Used > 10th group as OR reference

Crude OR for CHD in offspring:

B12 < 10th 1.8 (0.8 to 4)

No difference in vitamin B12 levels between cases and controls

Crude OR does not provide evidence for increased odds of CHD in offspring with low B12

Hobbs et al.

Median (min: max)

ng/L

Cases: 418.20 (94.21 to 957.30)

Controls: 454.50 (100.72 to 1,045.0)

Unadjusted p = .2569

Adjusted p = 0.3953 (age, race, education, income, cigarette use, alcohol consumption, vitamin intake, caffeine intake, interval pregnancy to testing)

No reference ranges. OR for association between case or control status and log transformed B12 concentration

aOR (other biomarkers: folate, homocysteine, methionine, SAH, SAM, adenosine), education, cigarette use, interval pregnancy to testing for CHD in offspring:

B12 1.35 (0.58 to 3.15) p = 0.4875

No difference in vitamin B12 levels between cases and controls

aOR does not provide evidence for increased odds of CHD in offspring in relation to B12

Folate

Dilli et al.

Mean ± SD

nmol/L

Serum folate

Cases: 22.27 ± 13.18

Controls: 22.27 ± 10.45

p = 0.94

Unable to calculate with available data

No difference in serum folate levels between cases and controls

No definition of reference ranges for deficiency and therefore OR not calculated

Verkleij Hagoort et al.

Median (min: max)

nmol/L

Serum folate

Cases: 15 (6.2 to 27.8)

Controls: 14.1 (6.4 to 40.3)

p > .05

RBC folate

Cases: 646 (299 to 1,343)

Controls: 630 (163 to 1,549)

p > .05

Utilized control group < 10th as reference ranges (<10.1 nmol/L serum, <431 nmol/L RBC). Used > 10th group as OR reference

Crude OR for CHD in offspring:

Serum folate<10th 1.3 (0.5 to 3.1)

RBC folate<10th 1.1 (0.4 to 2.6)

Higher levels of serum folate in cases than controls. However, not significant to 5% level when adjusted

aOR does not provide evidence for increased odds of CHD in offspring in relation to plasma folate

Hobbs et al.

Median (min: max)

mg/L

Plasma folate

Cases: 9.6 (1.86 to 30.23)

Controls: 10.66 (3.55 to 40.12)

Unadjusted p = 0.0174

Adjusted p = 0.1681 (age, race, education, income, cigarette use, alcohol consumption, vitamin intake, caffeine intake, interval pregnancy to testing)

No reference ranges. OR for association between case or control status and log transformed plasma folate concentration

aOR (other biomarkers: Folate, homocysteine, methionine, SAH, SAM, adenosine), education, cigarette use, interval pregnancy to testing for CHD in offspring:

Plasma folate 0.89 (0.41 to 1.96) p = 0.7781

No difference in folate levels between cases and controls

aOR does not provide evidence for increased odds of CHD in offspring in relation to B12

a

OR not calculated in original paper, therefore calculated by authors.

TABLE 2

Published reference ranges for micronutrients (Cunningham, 2010)

Micronutrient (unit)Not pregnantSecond trimester
Vitamin A (mg/L)0.2 to 10.35 to 0.44
Vitamin B12 (ng/L)279 to 966130 to 656
Vitamin D (nmol/L)34.94 to 199.6824.96 to 54.91
Ferritin (μg/L)10 to 1502 to 230
Serum folate (nmol/L)12.24 to 40.791.81 to 54.38
RBC folate (nmol/L)339.90 to 1,019.70213.00 to 1876.25
Copper (μg/L)700 to 1,4001,650 to 2,210
Selenium (μg/L)63 to 16075 to 145
Zinc (μg/dL)75 to 12051 to 80

Note: NR ‐ not recorded.

3.3.1
Vitamin D

Three studies assessed vitamin D levels between cases and controls (Dilli et al., 2018; Koster et al., 2018; Mokhtar et al., 2019). All three identified significantly lower levels of vitamin D in cases when compared to control samples. Two studies specified timing of maternal blood sampling (Dilli et al., 2018; Koster et al., 2018). The mean vitamin D levels in both cases and controls reported by Dilli et al., when compared to published reference ranges were classified as deficient.

ORs could not be calculated for this study from available data. Median vitamin D levels reported by Koster et al. for cases and controls were in the normal range for published reference ranges. This robust study design with a large sample size suggested an increased adjusted odds of CHD in vitamin D deficiency (1.82 [1.25 to 2.66]; p = .002). Confounders adjusted for included age, body mass index (BMI), ethnicity and smoking. However, deficiency was defined as <50 nmol/L, a higher value than in published literature (lower reference range 34.94 nmol/L).

Mokhtar et al. did not define timing of maternal blood sampling and as such vitamin D levels could not be compared to published reference ranges. Crude OR suggested no evidence for increased odds of CHD in vitamin D deficiency, defined as <50 nmol/L. However, this study had a small sample size of 50 cases and controls with odds ratios not adjusted for potential confounders.

3.3.2
Vitamin B12

Three studies assessed vitamin B12 levels between cases and controls (Dilli et al., 2018), with all three studies showing no significant difference in B12 levels. The mean vitamin B12 levels reported by Dilli et al. in cases and controls were both deficient when compared to published reference ranges. ORs could not be calculated from available data. The median vitamin B12 levels reported by Verkleij‐Hagoort et al. (2006) in cases and controls were both in the normal range when compared to published reference ranges.

Crude OR did not suggest an increase in odds of CHD in mothers with B12 deficiency. However, deficiency was defined as <159 ng/L which is significantly lower than published definition of deficiency. Therefore, this challenges this finding. The median vitamin B12 levels reported by Hobbs et al. (2005) in cases and controls were both in the normal range when compared to published reference ranges. Adjusted OR did not provide evidence of increased odds of CHD in lower vitamin B12.

However, no references for odds calculation were stipulated.

3.3.3
Folate

Three studies assessed folate levels between cases and controls, with all three studies showing no significant difference in folate levels (Dilli et al., 2018). ORs could not be calculated from available data for Dilli et al. OR presented by Verkleij‐Hagoort et al. and Hobbs et al. did not suggest an increase in odds of CHD in mothers with a lower folate. Dilli et al. and Verkleij‐Hagoort et al. assessed serum folate levels, with the mean or median level for both cases and controls within the normal range when compared to published reference ranges.

No available published reference values are available for plasma folate assessed by Hobbs et al.

3.3.4
Vitamin A

One study assessed vitamin A levels between cases and controls with no significant difference between the two groups (Dilli et al., 2018). The range of vitamin concentrations for both cases and controls were large, with the mean values above the upper end of published reference values for both cases and controls. Assessment was done in a small sample of 50 cases and 50 controls. ORs could not be calculated from available data.

3.3.5
Zinc

Two studies assessed zinc levels between cases and controls (Dilli et al., 2018; Hu et al., 2014). Hu et al. (2014) assessed hair concentrations of zinc. Analysis of hair did not identify any significant difference in levels of zinc between cases and controls. Crude and adjusted OR did not provide evidence for increased odds of CHD in offspring with high or low zinc. Published reference values for hair concentrations are not available and therefore control group 5th and 95th centiles were used as references for deficiency and excess.

Dilli et al. assessed serum concentrations and identified significantly higher levels of zinc in cases than controls. ORs could not be calculated for this study from available data. When compared to published reference ranges, mean zinc concentration of the control group was deficient while the case group was in the normal range. Furthermore, a small sample of 50 cases and 50 controls were assessed. These heterogenous studies test different maternal sample sites with contradictory findings.

3.3.6
Copper

Two studies assessed copper levels between cases and controls (Hu et al., 2014; Ou et al., 2017). Hu et al. assessed hair concentrations of copper, with significantly higher levels of copper in cases than controls. ORs adjusted for age, maternal residence, folic acid supplementation and previous pregnancy suggested an increased odds of CHD in higher copper hair concentrations (5.7 [2.58 to 12.61]). There was no evidence of increased odds of CHD in lower copper hair concentrations. This study was well designed, utilizing the 5th and 95th centiles of the control group copper levels as references for deficiency and excess due to lack of published reference values for hair concentrations.

Ou et al. assessed plasma concentrations of copper, with significantly lower levels of copper in cases than controls. However, crude OR did not provide evidence of increased odds of CHD in offspring of mothers with low copper. When plasma values were compared to published reference ranges, the median level in both cases and controls was deficient. The tertiles of control group data were utilized as reference for ORs and therefore, assessment of CHD risk relative to deficiency is limited. These heterogenous studies test different maternal sample sites with contradictory findings.

3.3.7
Selenium

One study assessed selenium levels between cases and controls (Ou et al., 2017). Lower levels of selenium were present in cases than in controls, with decreased adjusted odds of CHD in offspring with higher selenium levels. However, both cases and controls had higher median selenium levels than normal reference values, with the tertiles of control group utilized as references for OR calculation. While well designed, this limits assessment of CHD risk relative to selenium deficiency.

3.3.8
Ferritin

One study assessed ferritin levels between cases and controls (Yang et al., 2020), with significantly lower levels of ferritin present in cases. However, both cases and controls had ferritin levels within the normal range when compared to published reference ranges. Mixed linear regression modeling adjusting for maternal age, gestational age, residence, education, occupation, parity, passive smoking and folate supplementation suggested lower levels of serum ferritin in cases than controls. There was no definition or assessment of ferritin (iron) deficiency in analysis.

Furthermore, this was a small sample of 50 cases and 100 controls where biochemical analysis was performed.

3.4

Confounding variable assessment

Figure 2 summarizes the proportion of studies which accounted for individual confounding variables in their analysis of odds of CHD. Age was the most frequent confounder accounted for in 50% of studies, followed by maternal smoking status, maternal education, parity, folate supplementation and timing of maternal micronutrient sampling in 37.5% of studies. It is therefore clear that across the included studies, unaccounted for confounding variables may bias analyses presented.

FIGURE 2

Confounding variables that were adjusted for in included studies, proportion of studies

Figure image at the original source: open the original paper. This file is not included in this text import.
4

DISCUSSION

4.1

Main findings and interpretation

Assessing the eight micronutrients included in this systematic review, there is not enough evidence to confidently determine if maternal micronutrient deficiency increases the risk of CHD in fetuses. This is exemplified in the small sample sizes included from heterogenous studies, reporting contradictory findings. Studies included were all of case control design. Data from randomized controlled or controlled trials was not available.

Included studies suggested lower levels of vitamin D, selenium and ferritin in cases than controls; no difference in levels of vitamin B12, folate and vitamin A; and contradictory findings for zinc and copper (Dilli et al., 2018; Hobbs et al., 2005; Hu et al., 2014; Koster et al., 2018; Mokhtar et al., 2019; Ou et al., 2017; Verkleij‐Hagoort et al., 2006; Yang et al., 2020). Deficiency is defined as “a shortage of a substance (as vitamins) necessary to health” (Merriam‐Webster, 2021).

Pregnancy is a state of altered physiology and metabolism which can influence laboratory test value ranges (Cunningham, 2010). Reference values are rarely reported for pregnancy. In this systematic review, we compared median or mean micronutrient levels for cases and controls to published reference ranges established by systematic review of literature utilizing the 2.5 to 97.5 centiles as a normal range (Cunningham, 2010). When compared to these published reference ranges, mean or median values reported for cases and controls in studies were often both deficient or both in the normal range.

For vitamin D and vitamin B12 where deficiency was assessed by ORs, deficiency threshold defined in the studies differed from published reference ranges, limiting these findings (Koster et al., 2018; Mokhtar et al., 2019; Verkleij‐Hagoort et al., 2006). Furthermore, published reference ranges are only available for blood samples and not hair (Hu et al., 2014). One study of copper and zinc utilized hair sampling as opposed to blood sampling (Hu et al., 2014). While well designed, it is unclear whether control group references are representative of the population.

This could contribute to the contradictory findings in these micronutrients. Therefore, across the eight micronutrients studied, true assessment of deficiency has not been performed and limits conclusions drawn.

Numerous factors influence micronutrient levels including BMI, age, ethnicity and a number of lifestyle factors such as smoking (Damms‐Machado et al., 2012; Kant & Graubard, 2007; Preston, 1991; Richard & Roussel, 1999). Of the eight papers included, five adjusted for confounders in their analysis (Hobbs et al., 2005; Hu et al., 2014; Koster et al., 2018; Ou et al., 2017; Yang et al., 2020). However, as Figure 2 illustrates, adjustments for confounders were limited with factors such as ethnicity only being recognized in 12.5% of studies.

Furthermore, pregnancy and gestational age are known to influence blood micronutrient levels (Cunningham, 2010). This is particularly important for systematic review given the heterogeneity of timing of sampling in the included studies. Of the included studies, four sampled postnatally, two antenatally and two did not specify timing. However, given the critical sensitive period for cardiac development of 3 to 8 weeks, nutrition in the periconceptual period is likely most relevant (Moore et al., 2020). Studies assessing micronutrient levels and dietary patterns suggest that postnatal assessment of a number of micronutrients including vitamin B12, folate and zinc represents that of the periconceptual period (Cucó et al., 2006; Devine et al., 2000; van Driel et al., 2010).

However, sample sizes were small, with only 30 patients in the direct study of micronutrient levels (van Driel et al., 2010). Furthermore, this was performed in fertility patients, potentially unrepresentative of the general population (van Driel et al., 2010). Therefore, the sample timings in included studies may not accurately represent periconceptual and early pregnancy levels, limiting findings.

Despite these limitations, there remains biological and physiological plausibility for specific micronutrient deficiencies being associated with fetal CHD. Micronutrients are known to play essential roles in cellular signaling, growth and development (McArdle & Ashworth, 1999). Vitamin D deficiency is a significant public health issue, with prevalence reported in 40 to 80% of the pregnant population. Maternal and fetal concentrations increase by up to 200% in the first trimester, with vitamin D acting on gene expression to influence long term health (Kaludjerovic & Vieth, 2010).

Animal models have demonstrated knockdown of the vitamin D receptor is characterized by CHD (Kwon, 2016). Selenium performs biological function within selenoproteins, involved in vast physiological processes including protecting cells from oxidative stress (Labunskyy et al., 2014). Iron deficiency anemia is common in pregnancy, affecting approximately 20% of women in developed countries (Allen, 2000). Animal modeling of iron deficiency and defects in the transferrin receptor have been associated with neural tube and cardiovascular defects in animal models (Andersen et al., 2006; Hoyle et al., 1996).

These associations and biological roles stress the importance of future research in this field.

4.2

Strengths and limitations

This study was the first to address this topic and performed a robust review with clear inclusion criteria and population definitions. Further comparison to established published reference ranges strengthens the findings. This facilitates objective comparison across studies and illustrates the heterogeneity of results. The use of recognized reference ranges defining deficiency is essential in future studies in this field. However, there are limitations. The inclusion of observational studies introduces uncertainty through their inherent limitations including susceptibility to bias and confounding.

Inclusion and performance of such studies is necessitated in this subject area where controlled studies will not be available. Therefore, comparisons of case and control groups with full recognition of confounders in analysis is key for future research. The heterogeneity of studies including populations, CHD included and timings and methods of sample analysis prevented meta‐analysis. Therefore, the study focused on a narrative synthesis. Utilization of classifications of CHD such as those provided by EUROCAT and increased sample sizes with subgroup analyses could reduce heterogeneity and strengthen future findings (EUROCAT, 2013).

5

CONCLUSION

In conclusion, there is not enough evidence to confidently determine if maternal micronutrient deficiency increases the risk of CHD in fetuses. Further studies are required with prospective or nested case control design utilizing established micronutrient reference ranges ideally collecting samples in pregnancy and postnatally. The UK‐based Surgical‐PEARL (Surgical Paediatric congEnital Anomalies Registry with Long term follow‐up) multicenter cohort study has commenced recruitment in 2022 (https://www.isrctn.com/ISRCTN12557586). This will recruit fetuses with congenital anomalies potentially requiring surgery and their biological mothers and fathers at the time of diagnosis, collecting routine clinical and imaging data, postnatal surgical data and a range of fetal, childhood and parental biosamples.

Through resources such as this and others, we aim to establish a greater evidence base to robustly answer this question.

AUTHOR CONTRIBUTIONS

SM conceived and designed the study; acquired, analyzed and interpreted the data; and drafted and approved the manuscript. CS conceived and designed the study; acquired, analyzed and interpreted the data; and drafted and approved the manuscript. MC contributed to study design; and drafted and approved the manuscript. TO contributed to study design; and drafted and approved the manuscript.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

Supporting information

Figure S1Detailed search strategy for MEDLINE, EMBASE, and Cochrane Library.

Click here for additional data file.

Supplement file at the original source: open the original paper. This file is not included in this text import.

Table S1 Characteristics of included studies. ASD, atrial septal defect; AVSD, atrioventricular septal defect; AV, aortic valve; DORV, double outlet right valve; HLHS, hypoplastic left heart syndrome; LVOT, left ventricular outflow tract; PDA, patent ductus arteriosus; PV, pulmonary valve; RVOT, right ventricular outflow tract; TGA, transposition of the great arteries; ToF, tetralogy of fallot; VSD, ventricular septal defect. † Methodology checklist classification derived utilizing the Scottish Intercollegiate Guidelines Network (SIGN) case control study risk of bias tool by two authors (SM and CS).

Assessment of subject selection, exposure assessment, confounding and statistical analysis classifies studies overall as high quality (++), acceptable (+) or unacceptable (−).

Click here for additional data file.

Supplement file at the original source: open the original paper. This file is not included in this text import.

ACKNOWLEDGEMENT

This study was supported by the Oyster Foundation through funding the role of a fetal medicine clinical research fellow.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

Allen , L. H. (2000 ). Anemia and iron deficiency: Effects on pregnancy outcome . The American Journal of Clinical Nutrition , 71 (5 ), 1280SNot reported1284S . 10.1093/ajcn/71.5.1280s 10799402
Andersen , H. S. , Gambling , L. , Holtrop , G. , & McArdle , H. J. (2006 ). Maternal iron deficiency identifies critical windows for growth and cardiovascular development in the rat postimplantation embryo . The Journal of Nutrition , 136 (5 ), 1171Not reported1177 . 10.1093/jn/136.5.1171 16614400
Blue , G. M. , Kirk , E. P. , Sholler , G. F. , Harvey , R. P. , & Winlaw , D. S. (2012 ). Congenital heart disease: Current knowledge about causes and inheritance . The Medical Journal of Australia , 197 (3 ), 155Not reported159 . 10.5694/mja12.10811 22860792
Botto , L. D. , & Correa , A. (2003 ). Decreasing the burden of congenital heart anomalies: An epidemiologic evaluation of risk factors and survival . Progress in Pediatric Cardiology , 18 (2 ), 111Not reported121 . 10.1016/S1058-9813(03)00084-5
Botto , L. D. , Olney , R. S. , & Erickson , J. D. (2004 ). Vitamin supplements and the risk for congenital anomalies other than neural tube defects . American Journal of Medical Genetics. Part C, Seminars in Medical Genetics , 125c (1 ), 12Not reported21 . 10.1002/ajmg.c.30004 14755429
Cucó , G. , Fernández‐Ballart , J. , Sala , J. , Viladrich , C. , Iranzo , R. , Vila , J. , & Arija , V. (2006 ). Dietary patterns and associated lifestyles in preconception, pregnancy and postpartum . European Journal of Clinical Nutrition , 60 (3 ), 364Not reported371 . 10.1038/sj.ejcn.1602324 16340954
Cunningham , F. G. (2010 ). Laboratory values in normal pregnancy. Protocols for high risk pregnancies: An evidence based approach (5th ed.). New Jersey: Blackwell Science Limited.
Damms‐Machado , A. , Weser , G. , & Bischoff , S. C. (2012 ). Micronutrient deficiency in obese subjects undergoing low calorie diet . Nutrition Journal , 11 (1 ), 34. 10.1186/1475-2891-11-34 22657586 PMC3404899
Devine , C. M. , Bove , C. F. , & Olson , C. M. (2000 ). Continuity and change in women's weight orientations and lifestyle practices through pregnancy and the postpartum period: The influence of life course trajectories and transitional events . Social Science & Medicine , 50 (4 ), 567Not reported582 . 10.1016/S0277-9536(99)00314-7 10641808
Dilli , D. , Doǧan , N. N. , Örün , U. A. , Koç , M. , Zenciroǧlu , A. , Karademir , S. , & Akduman , H. (2018 ). Maternal and neonatal micronutrient levels in newborns with CHD . Cardiology in the Young , 28 (4 ), 523Not reported529 . 10.1017/S1047951117002372 29357951
EUROCAT (2013 ). In University Of Ulster (Ed.), EUROCAT guide 1.4: Instruction for the registration of congenital anomalies . University of Ulster, U Northern Ireland: EUROCAT Central Registry.
Feng , Y. , Wang , S. , Chen , R. , Tong , X. , Wu , Z. , & Mo , X. (2015 ). Maternal folic acid supplementation and the risk of congenital heart defects in offspring: A meta‐analysis of epidemiological observational studies . Scientific Reports , 5 , Article 8506 . 10.1038/srep08506 25687545 PMC4330542
Hobbs , C. A. , Cleves , M. A. , Melnyk , S. , Zhao , W. , & James , S. J. (2005 ). Congenital heart defects and abnormal maternal biomarkers of methionine and homocysteine metabolism . American Journal of Clinical Nutrition , 81 (1 ), 147Not reported153 . 10.1093/ajcn/81.1.147 15640474
Hoyle , C. , Henderson , D. J. , Matthews , D. J. , & Copp , A. J. (1996 ). Transferrin and its receptor in the development of genetically determined neural tube defects in the mouse embryo . Developmental Dynamics , 207 (1 ), 35Not reported46 . 10.1002/(sici)1097-0177(199609)207:1<35::Aid-aja4>3.0.Co;2-x 8875074
Hu , H. , Liu , Z. , Li , J. , Li , S. , Tian , X. , Lin , Y. , … Zhu , J. (2014 ). Correlation between congenital heart defects and maternal copper and zinc concentrations . Birth Defects Research Part A: Clinical and Molecular Teratology , 100 (12 ), 965Not reported972 . 10.1002/bdra.23284 25131520
Ingrid Goh , Y. , Bollano , E. , Einarson , T. R. , & Koren , G. (2006 ). Prenatal multivitamin supplementation and rates of congenital anomalies: A meta‐analysis . Journal of Obstetrics and Gynaecology Canada , 28 (8 ), 680Not reported689 . 10.1016/S1701-2163(16)32227-7 17022907
Joshi , R. O. , Chellappan , S. , & Kukshal , P. (2020 ). Exploring the role of maternal nutritional epigenetics in congenital heart disease . Current Developments in Nutrition , 4 (11 ), nzaa166. 10.1093/cdn/nzaa166 33294766 PMC7703391
Kalisch‐Smith , J. I. , Ved , N. , Szumska , D. , Munro , J. , Troup , M. , Harris , S. E. , … Sparrow , D. B. (2021 ). Maternal iron deficiency perturbs embryonic cardiovascular development in mice . Nature Communications , 12 (1 ), 3447. 10.1038/s41467-021-23660-5 PMC8187484 34103494
Kaludjerovic , J. , & Vieth , R. (2010 ). Relationship between vitamin D during perinatal development and health . Journal of Midwifery and Women's Health , 55 (6 ), 550Not reported560 . 10.1016/j.jmwh.2010.02.016 20974417
Kant , A. K. , & Graubard , B. I. (2007 ). Ethnicity is an independent correlate of biomarkers of micronutrient intake and status in American adults . The Journal of Nutrition , 137 (11 ), 2456Not reported2463 . 10.1093/jn/137.11.2456 17951485
Koster , M. P. H. , van Duijn , L. , Krul‐Poel , Y. H. M. , Laven , J. S. , Helbing , W. A. , Simsek , S. , & Steegers‐Theunissen , R. P. M. (2018 ). A compromised maternal vitamin D status is associated with congenital heart defects in offspring . Early Human Development , 117 , 50Not reported56 . 10.1016/j.earlhumdev.2017.12.011 29287191
Kwon , H. J. (2016 ). Vitamin D receptor signaling is required for heart development in zebrafish embryo . Biochemical and Biophysical Research Communications , 470 (3 ), 575Not reported578 . 10.1016/j.bbrc.2016.01.103 26797277
Labunskyy , V. M. , Hatfield , D. L. , & Gladyshev , V. N. (2014 ). Selenoproteins: Molecular pathways and physiological roles . Physiological Reviews , 94 (3 ), 739Not reported777 . 10.1152/physrev.00039.2013 24987004 PMC4101630
McArdle , H. J. , & Ashworth , C. J. (1999 ). Micronutrients in fetal growth and development . British Medical Bulletin , 55 (3 ), 499Not reported510 . 10.1258/0007142991902574 10746341
Merriam‐Webster . (2021 ). Medical defintion of deficiency . https://www.merriam-webster.com/dictionary/deficiency#medicalDictionary
Mitchell , S. C. , Korones , S. B. , & Berendes , H. W. (1971 ). Congenital heart disease in 56,109 births. Incidence and natural history . Circulation , 43 (3 ), 323Not reported332 . 10.1161/01.cir.43.3.323 5102136
Mokhtar , W. A. , Fawzy , A. , Allam , R. M. , Amer , R. M. , & Hamed , M. S. (2019 ). Maternal vitamin D level and vitamin D receptor gene polymorphism as a risk factor for congenital heart diseases in offspring; an Egyptian case: control study . Genes and Diseases , 6 (2 ), 193Not reported200 . 10.1016/j.gendis.2018.08.001 31194013 PMC6545446
Moore , K. , Persaud , T. V. N. , & Torchia , M. (2020 ). Cardiovascular system: The developing human. In The developing human: Clinically oriented embryology (11th ed., pp. 263Not reported314 ). Amsterdam: Elsevier.
National Institute for Health and Care Excellence . (2014 ). Maternal and child nutrition . https://www.nice.org.uk/guidance/ph11/chapter/4-recommendations
National Institute for Health and Care Excellence . (2017 ). Vitamin D: Supplement use in specific population groups . https://www.nice.org.uk/guidance/ph56/chapter/1-Recommendations
Ou , Y. , Bloom , M. S. , Nie , Z. , Han , F. , Mai , J. , Chen , J. , … Zhuang , J. (2017 ). Associations between toxic and essential trace elements in maternal blood and fetal congenital heart defects . Environment International , 106 , 127Not reported134 . 10.1016/j.envint.2017.05.017 28645012
Page , M. J. , McKenzie , J. E. , Bossuyt , P. M. , Boutron , I. , Hoffmann , T. C. , Mulrow , C. D. , … Moher, D. (2021 ). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews . BMJ , 372 , n71. 10.1136/bmj.n71 33782057 PMC8005924
Petrini , J. , Damus , K. , Russell , R. , Poschman , K. , Davidoff , M. J. , & Mattison , D. (2002 ). Contribution of birth defects to infant mortality in the United States . Teratology , 66 (Suppl 1 ), S3Not reportedS6 . 10.1002/tera.90002 12239736
Preferred Reporting Items for Systematic Reviews and Meta‐Analyses . (2020 ). PRISMA 2020 checklist . http://www.prisma-statement.org/PRISMAStatement/Checklist
Preston , A. M. (1991 ). Cigarette smoking‐nutritional implications . Progress in Food & Nutrition Science , 15 (4 ), 183Not reported217 . 1784736
Public Health England (2019 ). National congenital anomaly and rare disease registration service: Congenital anomaly statistics 2019 . https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1021335/NCARDRS_congenital_anomaly_statistics_report_2019.pdf
Richard , M. J. , & Roussel , A. M. (1999 ). Micronutrients and ageing: Intakes and requirements . The Proceedings of the Nutrition Society , 58 (3 ), 573Not reported578 . 10.1017/s0029665199000750 10604189
Royal College of Obstetricians and Gynaecologists . (2014 ). Healthy eating and vitamin supplements in pregnancy . https://www.rcog.org.uk/globalassets/documents/patients/patient-information-leaflets/pregnancy/pi-healthy-eating-and-vitamin-supplements-in-pregnancy.pdf
Scottish Intercollegiate Guidelines Network . (2012 ). Methodology checklist 4: Case: control studies . Edinburgh: Healthcare Improvement Scotland. https://www.sign.ac.uk/what-we-do/methodology/checklists/
Shenkin , A. (2006 ). Micronutrients in health and disease . Postgraduate Medical Journal , 82 (971 ), 559Not reported567 . 10.1136/pgmj.2006.047670 16954450 PMC2585731
Suluba , E. , Shuwei , L. , Xia , Q. , & Mwanga , A. (2020 ). Congenital heart diseases: Genetics, non‐inherited risk factors, and signaling pathways . Egyptian Journal of Medical Human Genetics , 21 (1 ), 11Not reported12 . 10.1186/s43042-020-0050-1
Tennant , P. W. , Pearce , M. S. , Bythell , M. , & Rankin , J. (2010 ). 20‐Year survival of children born with congenital anomalies: A population‐based study . Lancet , 375 (9715 ), 649Not reported656 . 10.1016/s0140-6736(09)61922-x 20092884
van Driel , L. M. J. W. , Zwolle , L. J. H. , de Vries , J. H. M. , Boxmeer , J. C. , Lindemans , J. , Steegers , E. A. P. , & Steegers‐Theunissen , R. P. M. (2010 ). The preconception nutritional status of women undergoing fertility treatment: Use of a one‐year post‐delivery assessment . E‐SPEN, the European e‐Journal of Clinical Nutrition and Metabolism , 5 (6 ), e284Not reportede291 . 10.1016/j.eclnm.2010.10.004
Verkleij‐Hagoort , A. C. , Verlinde , M. , Ursem , N. T. C. , Lindemans , J. , Helbing , W. A. , Ottenkamp , J. , … Steegers‐Theunissen , R. P. M. (2006 ). Maternal hyperhomocysteinaemia is a risk factor for congenital heart disease . BJOG: An International Journal of Obstetrics and Gynaecology , 113 (12 ), 1412Not reported1418 . http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med6&NEWS=N&AN=17081182 17081182 10.1111/j.1471-0528.2006.01109.x
Yang , J. , Kang , Y. , Cheng , Y. , Zeng , L. , Shen , Y. , Shi , G. , … Dang , S. (2020 ). Iron intake and iron status during pregnancy and risk of congenital heart defects: A case: control study . International Journal of Cardiology , 301 , 74Not reported79 . 10.1016/j.ijcard.2019.11.115 31767385
Publication and source details

Original title: Maternal micronutrient deficiency and congenital heart disease risk: A systematic review of observational studies

Stuart Mires; Massimo Caputo; Timothy Overton; Clare Skerritt

Birth Defects Research · 2022

* Correspondence
Stuart Mires, University of Bristol, St Michael's Hospital, Southwell Street, Bristol BS2 8EG, United Kingdom.
Email: stuart.mires@bristol.ac.uk
© 2022 The Authors. Birth Defects Research published by Wiley Periodicals LLC.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Oyster Foundation

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T08:47:47.217040+00:00

DOI: 10.1002/bdr2.2072 · PMC9805156